Two	NN	O	O
other	NN	O	O
T	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
CEM	NN	O	B-cell_line
and	NN	O	O
RPMI	NN	O	B-cell_line
8402	NN	O	I-cell_line
,	NN	O	O
have	NN	O	O
essentially	NN	O	O
identical	NN	O	O
deletions	NN	O	O
.	NN	O	O

A	NN	O	O
similar	NN	O	O
,	NN	O	O
heat	NN	O	O
labile	NN	O	O
activity	NN	O	O
which	NN	O	O
altered	NN	O	O
mobility	NN	O	O
of	NN	O	O
the	NN	O	O
TR	NN	O	B-protein
:	NN	O	I-protein
TRE	NN	O	I-protein
complex	NN	O	I-protein
was	NN	O	O
also	NN	O	O
present	NN	O	O
in	NN	O	O
NE	NN	O	O
from	NN	O	O
T3-unresponsive	NN	O	B-cell_line
JEG-3	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

TNF-alpha	NN	O	B-RNA
RNA	NN	O	I-RNA
was	NN	O	O
undetectable	NN	O	O
in	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
whereas	NN	O	O
a	NN	O	O
low	NN	O	O
constitutive	NN	O	O
level	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
U9-IIIB	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

TNF-alpha	NN	O	B-protein
was	NN	O	O
able	NN	O	O
to	NN	O	O
increase	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
LTR	NN	O	I-DNA
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
but	NN	O	O
in	NN	O	O
monocytic	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
TNF-alpha	NN	O	B-protein
did	NN	O	O
not	NN	O	O
induce	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
LTR	NN	O	I-DNA
above	NN	O	O
a	NN	O	O
constitutive	NN	O	O
level	NN	O	O
of	NN	O	O
activity	NN	O	O
.	NN	O	O

Using	NN	O	O
supercoiled	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
linear	NN	O	O
templates	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
differences	NN	O	O
in	NN	O	O
transcription	NN	O	O
efficiencies	NN	O	O
from	NN	O	O
templates	NN	O	O
lacking	NN	O	O
or	NN	O	O
disrupting	NN	O	O
the	NN	O	O
X	NN	O	B-DNA
consensus	NN	O	I-DNA
element	NN	O	I-DNA
that	NN	O	O
reflect	NN	O	O
effects	NN	O	O
of	NN	O	O
random	NN	O	O
replacement	NN	O	O
of	NN	O	O
X	NN	O	B-DNA
box	NN	O	I-DNA
sequences	NN	O	I-DNA
in	NN	O	O
transient	NN	O	O
expression	NN	O	O
assays	NN	O	O
.	NN	O	O

Steroid	NN	O	O
dose	NN	O	O
sparing	NN	O	O
:	NN	O	O
pharmacodynamic	NN	O	O
responses	NN	O	O
to	NN	O	O
single	NN	O	O
versus	NN	O	O
divided	NN	O	O
doses	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Inhibitory	NN	O	O
drug	NN	O	O
interactions	NN	O	O
affecting	NN	O	O
the	NN	O	O
metabolism	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
(	NN	O	O
MP	NN	O	O
)	NN	O	O
may	NN	O	O
produce	NN	O	O
either	NN	O	O
steroid	NN	O	O
sparing	NN	O	O
or	NN	O	O
adverse	NN	O	O
effects	NN	O	O
partly	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
exposure	NN	O	O
time	NN	O	O
to	NN	O	O
the	NN	O	O
steroid	NN	O	O
.	NN	O	O

Two	NN	O	O
types	NN	O	O
of	NN	O	O
responses	NN	O	O
were	NN	O	O
compared	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
MP	NN	O	O
dose	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
bolus	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
divided	NN	O	O
regimen	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
bolus	NN	O	O
and	NN	O	O
a	NN	O	O
5	NN	O	O
mg	NN	O	O
bolus	NN	O	O
8	NN	O	O
hours	NN	O	O
later	NN	O	O
)	NN	O	O
in	NN	O	O
six	NN	O	O
healthy	NN	O	O
male	NN	O	O
volunteers	NN	O	O
.	NN	O	O

The	NN	O	O
37.5	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
dose	NN	O	O
produced	NN	O	O
a	NN	O	O
23	NN	O	O
%	NN	O	O
overall	NN	O	O
decreased	NN	O	O
blood	NN	O	O
histamine	NN	O	O
response	NN	O	O
.	NN	O	O

The	NN	O	O
decline	NN	O	O
and	NN	O	O
return	NN	O	O
of	NN	O	O
cortisol	NN	O	O
concentrations	NN	O	O
were	NN	O	O
similar	NN	O	O
between	NN	O	O
MP	NN	O	O
treatments	NN	O	O
with	NN	O	O
suppression	NN	O	O
continuing	NN	O	O
for	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

-DOCSTART-	O

Our	NN	O	O
data	NN	O	O
strengthen	NN	O	O
the	NN	O	O
idea	NN	O	O
of	NN	O	O
a	NN	O	O
close	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
erythrocytic	NN	O	B-cell_line
and	NN	O	I-cell_line
the	NN	O	I-cell_line
megakaryocytic	NN	O	I-cell_line
lineages	NN	O	I-cell_line
and	NN	O	O
could	NN	O	O
also	NN	O	O
explain	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
markers	NN	O	O
specific	NN	O	O
to	NN	O	O
the	NN	O	O
erythrocytic	NN	O	B-cell_type
and	NN	O	I-cell_type
megakaryocytic	NN	O	I-cell_type
lineages	NN	O	I-cell_type
in	NN	O	O
most	NN	O	O
erythroblastic	NN	O	B-cell_line
and	NN	O	I-cell_line
megakaryoblastic	NN	O	I-cell_line
permanent	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

A	NN	O	O
block	NN	O	O
to	NN	O	O
RNA	NN	O	O
elongation	NN	O	O
is	NN	O	O
largely	NN	O	O
responsible	NN	O	O
for	NN	O	O
decreased	NN	O	O
c-myc	NN	O	B-DNA
transcription	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
monoclonal	NN	O	O
antibodies	NN	O	O
directed	NN	O	O
against	NN	O	O
ER	NN	O	B-protein
has	NN	O	O
been	NN	O	O
applied	NN	O	O
to	NN	O	O
the	NN	O	O
study	NN	O	O
of	NN	O	O
breast	NN	O	O
carcinomas	NN	O	O
and	NN	O	O
results	NN	O	O
obtained	NN	O	O
show	NN	O	O
good	NN	O	O
correlation	NN	O	O
with	NN	O	O
the	NN	O	O
quantitative	NN	O	O
SBA	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
recombinant	NN	O	O
retroviruses	NN	O	O
to	NN	O	O
characterize	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
an	NN	O	O
exogenous	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
primary	NN	O	O
cells	NN	O	O
obtained	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
lymphoproliferative	NN	O	O
disorders	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
rise	NN	O	O
of	NN	O	O
A10	NN	O	B-protein
and	NN	O	O
B27	NN	O	B-protein
antigen	NN	O	I-protein
incidence	NN	O	O
compared	NN	O	O
to	NN	O	O
that	NN	O	O
in	NN	O	O
normal	NN	O	O
subjects	NN	O	O
allows	NN	O	O
these	NN	O	O
antigens	NN	O	O
to	NN	O	O
be	NN	O	O
considered	NN	O	O
genetic	NN	O	O
markers	NN	O	O
of	NN	O	O
Icenko-Cushing	NN	O	O
's	NN	O	O
syndrome	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
carrying	NN	O	O
B27	NN	O	B-protein
antigen	NN	O	I-protein
had	NN	O	O
lymphocytic	NN	O	O
receptor	NN	O	O
concentrations	NN	O	O
under	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
such	NN	O	O
in	NN	O	O
patients	NN	O	O
free	NN	O	O
of	NN	O	O
the	NN	O	O
antigen	NN	O	O
carriage	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
RWLeu-4	NN	O	B-cell_line
cells	NN	O	I-cell_line
with	NN	O	O
VD3	NN	O	O
induced	NN	O	O
24R-hydroxylase	NN	O	B-protein
activity	NN	O	O
,	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
responsiveness	NN	O	O
in	NN	O	O
many	NN	O	O
tissues	NN	O	O
.	NN	O	O

The	NN	O	O
failure	NN	O	O
to	NN	O	O
express	NN	O	O
a	NN	O	O
class	NN	O	B-DNA
II	NN	O	I-DNA
gene	NN	O	I-DNA
in	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
such	NN	O	O
mutant	NN	O	B-cell_line
line	NN	O	I-cell_line
has	NN	O	O
been	NN	O	O
mapped	NN	O	O
to	NN	O	O
the	NN	O	O
MHC	NN	O	B-DNA
class	NN	O	I-DNA
II	NN	O	I-DNA
X	NN	O	I-DNA
box	NN	O	I-DNA
,	NN	O	O
a	NN	O	O
conserved	NN	O	B-DNA
transcriptional	NN	O	I-DNA
element	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
region	NN	O	I-DNA
.	NN	O	O

These	NN	O	O
parents	NN	O	O
were	NN	O	O
entirely	NN	O	O
asymptomatic	NN	O	O
.	NN	O	O

[	NN	O	O
Estrogen	NN	O	B-protein
receptor	NN	O	I-protein
content	NN	O	O
of	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
in	NN	O	O
patients	NN	O	O
with	NN	O	O
systemic	NN	O	O
lupus	NN	O	O
erythematosus	NN	O	O
]	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
ER	NN	O	B-protein
content	NN	O	O
of	NN	O	O
lymphocytes	NN	O	B-cell_type
from	NN	O	O
the	NN	O	O
controls	NN	O	O
and	NN	O	O
that	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
SLE	NN	O	O
.	NN	O	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
ES-derived	NN	O	B-cell_type
embryoid	NN	O	I-cell_type
bodies	NN	O	I-cell_type
express	NN	O	O
the	NN	O	O
full	NN	O	O
complement	NN	O	O
of	NN	O	O
mouse	NN	O	B-DNA
embryonic	NN	O	I-DNA
globin	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
correct	NN	O	O
temporal	NN	O	O
order	NN	O	O
and	NN	O	O
that	NN	O	O
on	NN	O	O
further	NN	O	O
differentiation	NN	O	O
,	NN	O	O
a	NN	O	O
switch	NN	O	O
occurs	NN	O	O
to	NN	O	O
the	NN	O	O
fetal/adult	NN	O	B-DNA
genes	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
carboxy-terminal	NN	O	B-protein
domain	NN	O	I-protein
contains	NN	O	O
repeat	NN	O	O
structures	NN	O	O
found	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
proteins	NN	O	O
that	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
cell-cycle	NN	O	O
control	NN	O	O
of	NN	O	O
yeast	NN	O	O
and	NN	O	O
in	NN	O	O
tissue	NN	O	O
differentiation	NN	O	O
in	NN	O	O
Drosophila	NN	O	O
and	NN	O	O
Ceanorhabditis	NN	O	O
elegans	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
putative	NN	O	B-DNA
human	NN	O	I-DNA
oncogene	NN	O	I-DNA
bcl-3	NN	O	I-DNA
and	NN	O	O
in	NN	O	O
the	NN	O	O
ankyrin	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

High	NN	O	O
affinity	NN	O	O
aldosterone	NN	O	O
binding	NN	O	O
sites	NN	O	O
have	NN	O	O
not	NN	O	O
only	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
the	NN	O	O
classic	NN	O	O
target	NN	O	O
tissues	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
renal	NN	O	O
tubules	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
in	NN	O	O
non-classic	NN	O	O
target	NN	O	O
tissues	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
mammary	NN	O	O
gland	NN	O	O
,	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
,	NN	O	O
recently	NN	O	O
,	NN	O	O
human	NN	O	B-cell_type
mononuclear	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
an	NN	O	O
abnormal	NN	O	O
effector	NN	O	O
mechanism	NN	O	O
could	NN	O	O
be	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
mononuclear	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
from	NN	O	O
essential	NN	O	O
hypertensives	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
the	NN	O	O
positive	NN	O	O
cases	NN	O	O
occurred	NN	O	O
in	NN	O	O
female	NN	O	O
cases	NN	O	O
.	NN	O	O

Nuclear	NN	O	O
T3R	NN	O	B-protein
in	NN	O	O
lymphocytes	NN	O	B-cell_type
was	NN	O	O
determined	NN	O	O
by	NN	O	O
radio-ligand	NN	O	O
binding	NN	O	O
analysis	NN	O	O
.	NN	O	O

Lymphocyte	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
from	NN	O	O
vitamin	NN	O	O
D-dependent	NN	O	O
rickets	NN	O	O
type	NN	O	O
II	NN	O	O
show	NN	O	O
functional	NN	O	O
defects	NN	O	O
in	NN	O	O
the	NN	O	O
1	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	I-protein
25-dihydroxyvitamin	NN	O	I-protein
D3	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

Lymphocyte	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
were	NN	O	O
established	NN	O	O
from	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
vitamin	NN	O	O
D-dependent	NN	O	O
rickets	NN	O	O
,	NN	O	O
type	NN	O	O
II	NN	O	O
(	NN	O	O
VDDR-II	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
lines	NN	O	O
were	NN	O	O
established	NN	O	O
by	NN	O	O
infection	NN	O	O
with	NN	O	O
human	NN	O	O
T-lymphotrophic	NN	O	O
virus	NN	O	O
type	NN	O	O
I	NN	O	O
(	NN	O	O
HTLV-I	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
established	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
VDDR-II	NN	O	O
(	NN	O	O
Rh-	NN	O	O
VDR	NN	O	B-protein
,	NN	O	O
Sh-	NN	O	O
VDR	NN	O	B-protein
,	NN	O	O
and	NN	O	O
Ab-	NN	O	O
VDR	NN	O	B-protein
)	NN	O	O
showed	NN	O	O
no	NN	O	O
specific	NN	O	O
binding	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
to	NN	O	O
a	NN	O	O
receptor	NN	O	B-protein
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
cultured	NN	O	B-cell_line
cells	NN	O	I-cell_line
with	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
did	NN	O	O
not	NN	O	O
stimulate	NN	O	O
production	NN	O	O
of	NN	O	O
24	NN	O	O
,	NN	O	O
25-dihydroxy-vitamin	NN	O	O
D3	NN	O	O
(	NN	O	O
24	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
response	NN	O	O
which	NN	O	O
is	NN	O	O
diagnostic	NN	O	O
of	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
functional	NN	O	B-protein
1	NN	O	I-protein
,	NN	O	I-protein
25	NN	O	I-protein
(	NN	O	I-protein
OH	NN	O	I-protein
)	NN	O	I-protein
2D3	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

The	NN	O	O
capacity	NN	O	O
of	NN	O	O
the	NN	O	O
receptor	NN	O	B-protein
for	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
was	NN	O	O
low	NN	O	O
in	NN	O	O
Ro-VDR	NN	O	B-cell_line
.	NN	O	O

While	NN	O	O
Ro-VDR	NN	O	B-cell_line
cells	NN	O	I-cell_line
showed	NN	O	O
typical	NN	O	O
nuclear	NN	O	O
localization	NN	O	O
of	NN	O	O
the	NN	O	O
unoccupied	NN	O	B-protein
1	NN	O	I-protein
,	NN	O	I-protein
25	NN	O	I-protein
(	NN	O	I-protein
OH	NN	O	I-protein
)	NN	O	I-protein
2D3	NN	O	I-protein
receptor	NN	O	I-protein
,	NN	O	O
neither	NN	O	O
the	NN	O	O
unoccupied	NN	O	O
nor	NN	O	O
the	NN	O	O
occupied	NN	O	O
receptor	NN	O	B-protein
from	NN	O	O
A1-VDR	NN	O	B-cell_line
cells	NN	O	I-cell_line
was	NN	O	O
completely	NN	O	O
localized	NN	O	O
in	NN	O	O
the	NN	O	O
nucleus	NN	O	O
.	NN	O	O

Low	NN	O	O
levels	NN	O	O
of	NN	O	O
c-jun	NN	O	B-RNA
transcripts	NN	O	I-RNA
were	NN	O	O
detectable	NN	O	O
in	NN	O	O
untreated	NN	O	B-cell_line
HL-60	NN	O	I-cell_line
leukemic	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
increased	NN	O	O
significantly	NN	O	O
by	NN	O	O
6	NN	O	O
h	NN	O	O
,	NN	O	O
and	NN	O	O
reached	NN	O	O
near	NN	O	O
maximal	NN	O	O
levels	NN	O	O
by	NN	O	O
24	NN	O	O
h	NN	O	O
of	NN	O	O
exposure	NN	O	O
to	NN	O	O
32	NN	O	O
nM	NN	O	O
TPA	NN	O	O
.	NN	O	O

Similar	NN	O	O
findings	NN	O	O
were	NN	O	O
obtained	NN	O	O
with	NN	O	O
bryostatin	NN	O	O
1	NN	O	O
(	NN	O	O
10	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
another	NN	O	O
activator	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
and	NN	O	O
inducer	NN	O	O
of	NN	O	O
monocytic	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3	NN	O	O
(	NN	O	O
0.5	NN	O	O
microM	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
structurally	NN	O	O
distinct	NN	O	O
agent	NN	O	O
which	NN	O	O
also	NN	O	O
induces	NN	O	O
HL-60	NN	O	O
monocytic	NN	O	O
differentiation	NN	O	O
,	NN	O	O
increased	NN	O	O
c-jun	NN	O	B-DNA
expression	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
half-life	NN	O	O
of	NN	O	O
c-jun	NN	O	B-RNA
RNA	NN	O	I-RNA
in	NN	O	O
TPA-treated	NN	O	B-cell_line
HL-60	NN	O	I-cell_line
cells	NN	O	I-cell_line
exposed	NN	O	O
to	NN	O	O
cycloheximide	NN	O	O
and	NN	O	O
actinomycin	NN	O	O
D	NN	O	O
was	NN	O	O
greater	NN	O	O
than	NN	O	O
2	NN	O	O
h	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
different	NN	O	O
cellular	NN	O	B-protein
factors	NN	O	I-protein
were	NN	O	O
involved	NN	O	O
in	NN	O	O
E3	NN	O	O
regulation	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
as	NN	O	O
compared	NN	O	O
with	NN	O	O
HeLa	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
both	NN	O	O
DNA	NN	O	O
binding	NN	O	O
and	NN	O	O
transfection	NN	O	O
analysis	NN	O	O
with	NN	O	O
the	NN	O	O
E3	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
both	NN	O	O
cell	NN	O	O
types	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

Reversing	NN	O	O
the	NN	O	O
position	NN	O	O
and	NN	O	O
subsequent	NN	O	O
mutagenesis	NN	O	O
of	NN	O	O
the	NN	O	O
L1	NN	O	B-DNA
and	NN	O	O
L2	NN	O	B-DNA
domains	NN	O	I-DNA
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
primary	NN	O	B-DNA
sequence	NN	O	I-DNA
of	NN	O	O
these	NN	O	O
motifs	NN	O	O
rather	NN	O	O
than	NN	O	O
their	NN	O	O
position	NN	O	O
in	NN	O	O
the	NN	O	O
E3	NN	O	B-DNA
promoter	NN	O	I-DNA
was	NN	O	O
critical	NN	O	O
for	NN	O	O
regulating	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Strains	NN	O	O
with	NN	O	O
mutations	NN	O	O
in	NN	O	O
either	NN	O	O
gene	NN	O	O
of	NN	O	O
the	NN	O	O
regulatory	NN	O	B-DNA
pair	NN	O	I-DNA
(	NN	O	O
phoP	NN	O	B-DNA
[	NN	O	O
transcriptional	NN	O	B-DNA
activator	NN	O	I-DNA
]	NN	O	O
or	NN	O	O
phoQ	NN	O	B-DNA
[	NN	O	O
membrane	NN	O	B-protein
sensor	NN	O	I-protein
kinase	NN	O	I-protein
]	NN	O	O
)	NN	O	O
had	NN	O	O
increased	NN	O	O
sensitivities	NN	O	O
to	NN	O	O
defensin	NN	O	B-protein
.	NN	O	O

Stimulation	NN	O	O
of	NN	O	O
a	NN	O	O
human	NN	O	B-cell_line
T-cell	NN	O	I-cell_line
clone	NN	O	I-cell_line
with	NN	O	O
anti-CD3	NN	O	B-protein
or	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
induces	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
translocation	NN	O	O
but	NN	O	O
not	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
1	NN	O	O
enhancer-dependent	NN	O	O
transcription	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
resistance	NN	O	O
to	NN	O	O
vitamin	NN	O	O
D	NN	O	O
treatment	NN	O	O
in	NN	O	O
XLH	NN	O	O
can	NN	O	O
not	NN	O	O
be	NN	O	O
explained	NN	O	O
by	NN	O	O
hypophosphatemia	NN	O	O
alone	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
investigate	NN	O	O
this	NN	O	O
possibility	NN	O	O
,	NN	O	O
we	NN	O	O
measured	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
VDR	NN	O	B-protein
in	NN	O	O
PHA-activated	NN	O	B-cell_line
peripheral	NN	O	I-cell_line
mononuclear	NN	O	I-cell_line
cells	NN	O	I-cell_line
from	NN	O	O
10	NN	O	O
XLH	NN	O	O
patients	NN	O	O
.	NN	O	O

-DOCSTART-	O

Mammalian	NN	O	B-cell_type
cells	NN	O	I-cell_type
express	NN	O	O
two	NN	O	O
distinct	NN	O	O
forms	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
CREB	NN	O	I-protein
(	NN	O	O
cAMP	NN	O	B-protein
response	NN	O	I-protein
element	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
)	NN	O	O
that	NN	O	O
are	NN	O	O
apparently	NN	O	O
the	NN	O	O
products	NN	O	O
of	NN	O	O
alternative	NN	O	O
splicing	NN	O	O
of	NN	O	O
the	NN	O	O
CREB	NN	O	B-RNA
gene	NN	O	I-RNA
transcript	NN	O	I-RNA
.	NN	O	O

Here	NN	O	O
it	NN	O	O
is	NN	O	O
shown	NN	O	O
that	NN	O	O
the	NN	O	O
HIV-1	NN	O	O
viral	NN	O	O
particle	NN	O	O
contains	NN	O	O
multiple	NN	O	O
copies	NN	O	O
of	NN	O	O
the	NN	O	O
vpr	NN	O	B-protein
protein	NN	O	I-protein
.	NN	O	O

A	NN	O	O
novel	NN	O	O
B-cell	NN	O	B-protein
lineage-specific	NN	O	I-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
present	NN	O	O
at	NN	O	O
early	NN	O	O
but	NN	O	O
not	NN	O	O
late	NN	O	O
stages	NN	O	O
of	NN	O	O
differentiation	NN	O	O
.	NN	O	O

A	NN	O	O
novel	NN	O	O
B-cell-specific	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
BSAP	NN	O	B-protein
,	NN	O	O
was	NN	O	O
identified	NN	O	O
as	NN	O	O
a	NN	O	O
mammalian	NN	O	B-protein
homolog	NN	O	I-protein
of	NN	O	O
the	NN	O	O
sea	NN	O	B-protein
urchin	NN	O	I-protein
protein	NN	O	I-protein
TSAP	NN	O	B-protein
,	NN	O	O
which	NN	O	O
interacts	NN	O	O
with	NN	O	O
the	NN	O	O
promoters	NN	O	B-DNA
of	NN	O	O
four	NN	O	O
tissue-specific	NN	O	B-DNA
late	NN	O	I-DNA
histone	NN	O	I-DNA
H2A-2	NN	O	I-DNA
and	NN	O	I-DNA
H2B-2	NN	O	I-DNA
genes	NN	O	I-DNA
.	NN	O	O

This	NN	O	O
sequence	NN	O	B-DNA
motif	NN	O	I-DNA
is	NN	O	O
a	NN	O	O
binding	NN	O	O
site	NN	O	O
for	NN	O	O
nuclear	NN	O	B-protein
proteins	NN	O	I-protein
,	NN	O	O
the	NN	O	O
so-called	NN	O	O
octamer	NN	O	B-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
(	NN	O	O
Oct	NN	O	B-protein
or	NN	O	O
OTF	NN	O	B-protein
factors	NN	O	I-protein
)	NN	O	O
.	NN	O	O

Many	NN	O	O
of	NN	O	O
these	NN	O	O
may	NN	O	O
be	NN	O	O
created	NN	O	O
by	NN	O	O
alternative	NN	O	O
splicing	NN	O	O
of	NN	O	O
a	NN	O	O
primary	NN	O	B-RNA
transcript	NN	O	I-RNA
of	NN	O	O
one	NN	O	O
Oct	NN	O	O
factor	NN	O	O
gene	NN	O	O
and	NN	O	O
may	NN	O	O
serve	NN	O	O
a	NN	O	O
specific	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
fine	NN	O	O
tuning	NN	O	O
of	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Each	NN	O	O
binding	NN	O	B-DNA
site	NN	O	I-DNA
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
overall	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
enhancer	NN	O	B-DNA
,	NN	O	O
however	NN	O	O
no	NN	O	O
single	NN	O	O
element	NN	O	O
seems	NN	O	O
absolutely	NN	O	O
required	NN	O	O
for	NN	O	O
activity	NN	O	O
.	NN	O	O

For	NN	O	O
a	NN	O	O
better	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
Ig	NN	O	B-DNA
heavy	NN	O	I-DNA
chain	NN	O	I-DNA
enhancer	NN	O	I-DNA
components	NN	O	I-DNA
,	NN	O	O
we	NN	O	O
have	NN	O	O
cloned	NN	O	O
and	NN	O	O
analyzed	NN	O	O
individual	NN	O	O
sequence	NN	O	B-DNA
elements	NN	O	I-DNA
.	NN	O	O

We	NN	O	O
find	NN	O	O
that	NN	O	O
the	NN	O	O
factor	NN	O	O
that	NN	O	O
binds	NN	O	O
to	NN	O	O
the	NN	O	O
E3	NN	O	B-DNA
enhancer	NN	O	I-DNA
motif	NN	O	I-DNA
,	NN	O	O
CATGTGGC	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
ubiquitous	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
.	NN	O	O

Multiple	NN	O	B-DNA
regulatory	NN	O	I-DNA
elements	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
(	NN	O	O
HIV	NN	O	B-DNA
LTR	NN	O	I-DNA
)	NN	O	O
are	NN	O	O
required	NN	O	O
for	NN	O	O
activation	NN	O	O
of	NN	O	O
HIV	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
viruses	NN	O	O
containing	NN	O	O
mutations	NN	O	O
in	NN	O	O
either	NN	O	O
the	NN	O	O
TAR	NN	O	B-DNA
loop	NN	O	I-DNA
sequences	NN	O	I-DNA
or	NN	O	O
stem	NN	O	O
secondary	NN	O	O
structure	NN	O	O
which	NN	O	O
were	NN	O	O
very	NN	O	O
defective	NN	O	O
for	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
untreated	NN	O	O
Jurkat	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
gave	NN	O	O
nearly	NN	O	O
wild-type	NN	O	O
levels	NN	O	O
of	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
phorbol	NN	O	B-cell_line
ester-treated	NN	O	I-cell_line
Jurkat	NN	O	I-cell_line
cells	NN	O	I-cell_line
but	NN	O	O
not	NN	O	O
in	NN	O	O
phorbol	NN	O	B-cell_line
ester-treated	NN	O	I-cell_line
HeLa	NN	O	I-cell_line
or	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
kappa	NN	O	O
B-binding	NN	O	O
activity	NN	O	O
with	NN	O	O
the	NN	O	O
HIV	NN	O	B-DNA
enhancer	NN	O	I-DNA
is	NN	O	O
inhibited	NN	O	O
only	NN	O	O
if	NN	O	O
it	NN	O	O
is	NN	O	O
activated	NN	O	O
via	NN	O	O
the	NN	O	O
mitogen	NN	O	B-protein
phytohemagglutinin	NN	O	B-protein
whereas	NN	O	O
phorbol	NN	O	O
myristate	NN	O	O
acetate-mediated	NN	O	O
activation	NN	O	O
is	NN	O	O
completely	NN	O	O
insensitive	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

-DOCSTART-	O

Purification	NN	O	O
of	NN	O	O
TCF-1	NN	O	B-protein
alpha	NN	O	I-protein
,	NN	O	O
a	NN	O	O
T-cell-specific	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
that	NN	O	O
activates	NN	O	O
the	NN	O	O
T-cell	NN	O	B-DNA
receptor	NN	O	I-DNA
C	NN	O	I-DNA
alpha	NN	O	I-DNA
gene	NN	O	I-DNA
enhancer	NN	O	I-DNA
in	NN	O	O
a	NN	O	O
context-dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

Mutation	NN	O	O
of	NN	O	O
the	NN	O	O
TCF-1	NN	O	B-DNA
alpha	NN	O	I-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
diminished	NN	O	O
enhancer	NN	O	O
activity	NN	O	O
and	NN	O	O
disrupted	NN	O	O
the	NN	O	O
synergism	NN	O	O
observed	NN	O	O
in	NN	O	O
vivo	NN	O	O
between	NN	O	O
tandem	NN	O	B-DNA
enhancer	NN	O	I-DNA
repeats	NN	O	I-DNA
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
tissue-specific	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
MOPC	NN	O	B-DNA
141	NN	O	I-DNA
immunoglobulin	NN	O	I-DNA
heavy-chain	NN	O	I-DNA
gene	NN	O	I-DNA
was	NN	O	O
studied	NN	O	O
by	NN	O	O
using	NN	O	O
in	NN	O	O
vitro	NN	O	O
transcription	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
encoding	NN	O	O
the	NN	O	O
granulocyte-macrophage	NN	O	B-protein
colony-stimulating	NN	O	I-protein
factor	NN	O	I-protein
(	NN	O	O
GM-CSF	NN	O	B-protein
)	NN	O	O
is	NN	O	O
induced	NN	O	O
upon	NN	O	O
activation	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
phytohemagglutinin	NN	O	B-protein
and	NN	O	O
active	NN	O	O
phorbolester	NN	O	O
and	NN	O	O
upon	NN	O	O
expression	NN	O	O
of	NN	O	O
tax1	NN	O	B-protein
,	NN	O	O
a	NN	O	O
transactivating	NN	O	B-protein
protein	NN	O	I-protein
of	NN	O	O
the	NN	O	O
human	NN	O	O
T-cell	NN	O	O
leukemia	NN	O	O
virus	NN	O	O
type	NN	O	O
I	NN	O	O
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
of	NN	O	O
human	NN	O	B-cell_type
tonsillar	NN	O	I-cell_type
T-lymphocytes	NN	O	I-cell_type
with	NN	O	O
4-phorbol	NN	O	O
12-myristate	NN	O	O
13-acetate	NN	O	O
(	NN	O	O
PMA	NN	O	O
)	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
about	NN	O	O
two	NN	O	O
fold	NN	O	O
increase	NN	O	O
in	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
GR	NN	O	B-protein
)	NN	O	O
number	NN	O	O
,	NN	O	O
without	NN	O	O
any	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
receptor	NN	O	O
affinity	NN	O	O
.	NN	O	O

Alone	NN	O	O
,	NN	O	O
PMA	NN	O	O
and	NN	O	O
calcium	NN	O	O
ionophore	NN	O	O
A23187	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
,	NN	O	O
but	NN	O	O
together	NN	O	O
stimulated	NN	O	O
,	NN	O	O
like	NN	O	O
phytohaemagglutinin	NN	O	B-protein
(	NN	O	O
PHA	NN	O	B-protein
)	NN	O	O
,	NN	O	O
leucine	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
particular	NN	O	O
,	NN	O	O
thymidine	NN	O	O
incorporation	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
an	NN	O	O
excess	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
is	NN	O	O
needed	NN	O	O
to	NN	O	O
revert	NN	O	O
FK506-mediated	NN	O	O
inhibition	NN	O	O
of	NN	O	O
IL-2	NN	O	B-protein
production	NN	O	O
,	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
and	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
NF-AT	NN	O	B-protein
,	NN	O	O
a	NN	O	O
T-cell-specific	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
necessary	NN	O	O
for	NN	O	O
IL-2	NN	O	B-DNA
gene	NN	O	I-DNA
activation	NN	O	O
.	NN	O	O

After	NN	O	O
in	NN	O	O
vitro	NN	O	O
adherence	NN	O	O
,	NN	O	O
human	NN	O	O
monocytes	NN	O	O
had	NN	O	O
a	NN	O	O
biphasic	NN	O	O
increase	NN	O	O
in	NN	O	O
PDGF	NN	O	B-RNA
(	NN	O	I-RNA
B	NN	O	I-RNA
)	NN	O	I-RNA
mRNA	NN	O	I-RNA
with	NN	O	O
peaks	NN	O	O
at	NN	O	O
6	NN	O	O
h	NN	O	O
and	NN	O	O
13	NN	O	O
d	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
suggest	NN	O	O
that	NN	O	O
adherence	NN	O	O
results	NN	O	O
in	NN	O	O
increases	NN	O	O
of	NN	O	O
c-fos	NN	O	B-RNA
,	NN	O	I-RNA
c-jun	NN	O	I-RNA
,	NN	O	I-RNA
EGR2	NN	O	I-RNA
,	NN	O	I-RNA
and	NN	O	I-RNA
PDGF	NN	O	I-RNA
(	NN	O	I-RNA
B	NN	O	I-RNA
)	NN	O	I-RNA
mRNA	NN	O	I-RNA
.	NN	O	O

Modulation	NN	O	O
of	NN	O	O
these	NN	O	O
events	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
adherence	NN	O	O
offers	NN	O	O
a	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
differential	NN	O	O
priming	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
may	NN	O	O
be	NN	O	O
accomplished	NN	O	O
.	NN	O	O

-DOCSTART-	O

Similar	NN	O	O
constructs	NN	O	O
controlled	NN	O	O
by	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
or	NN	O	O
the	NN	O	O
entire	NN	O	O
interleukin-2	NN	O	B-DNA
enhancer	NN	O	I-DNA
show	NN	O	O
bimodal	NN	O	O
expression	NN	O	O
patterns	NN	O	O
during	NN	O	O
induction	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
thresholds	NN	O	O
set	NN	O	O
by	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
may	NN	O	O
be	NN	O	O
a	NN	O	O
common	NN	O	O
property	NN	O	O
of	NN	O	O
inducible	NN	O	B-DNA
genes	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
Epstein-Barr	NN	O	B-DNA
virus	NN	O	I-DNA
(	NN	O	I-DNA
EBV	NN	O	I-DNA
)	NN	O	I-DNA
BMRF1	NN	O	I-DNA
promoter	NN	O	I-DNA
for	NN	O	O
early	NN	O	B-protein
antigen	NN	O	I-protein
(	NN	O	O
EA-D	NN	O	B-protein
)	NN	O	O
is	NN	O	O
regulated	NN	O	O
by	NN	O	O
the	NN	O	O
EBV	NN	O	B-protein
transactivators	NN	O	I-protein
,	NN	O	O
BRLF1	NN	O	B-protein
and	NN	O	O
BZLF1	NN	O	B-protein
,	NN	O	O
in	NN	O	O
a	NN	O	O
cell-specific	NN	O	O
manner	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
(	NN	O	O
BMRF1	NN	O	B-DNA
)	NN	O	O
for	NN	O	O
this	NN	O	O
early	NN	O	O
gene	NN	O	O
by	NN	O	O
studying	NN	O	O
its	NN	O	O
responsiveness	NN	O	O
in	NN	O	O
vitro	NN	O	O
to	NN	O	O
two	NN	O	O
immediate-early	NN	O	B-protein
viral	NN	O	I-protein
transactivators	NN	O	I-protein
,	NN	O	O
BZLF1	NN	O	B-protein
(	NN	O	O
Z	NN	O	B-protein
)	NN	O	O
and	NN	O	O
BRLF1	NN	O	B-protein
(	NN	O	O
R	NN	O	B-protein
)	NN	O	O
,	NN	O	O
focusing	NN	O	O
on	NN	O	O
the	NN	O	O
differences	NN	O	O
in	NN	O	O
response	NN	O	O
in	NN	O	O
lymphoid	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
epithelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
epithelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
the	NN	O	O
Z	NN	O	B-protein
transactivator	NN	O	I-protein
alone	NN	O	O
produced	NN	O	O
maximal	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
EA-D	NN	O	B-DNA
promoter	NN	O	I-DNA
;	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
R	NN	O	B-protein
and	NN	O	O
Z	NN	O	B-protein
together	NN	O	O
was	NN	O	O
no	NN	O	O
greater	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
Z	NN	O	B-protein
alone	NN	O	O
.	NN	O	O

-DOCSTART-	O

Complementary	NN	O	B-DNA
DNA	NN	O	I-DNA
encoding	NN	O	O
the	NN	O	O
human	NN	O	B-protein
T-cell	NN	O	I-protein
FK506-binding	NN	O	I-protein
protein	NN	O	I-protein
,	NN	O	O
a	NN	O	O
peptidylprolyl	NN	O	B-protein
cis-trans	NN	O	I-protein
isomerase	NN	O	I-protein
distinct	NN	O	O
from	NN	O	O
cyclophilin	NN	O	B-protein
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
Jurkat	NN	O	B-cell_line
leukemic	NN	O	I-cell_line
T	NN	O	I-cell_line
cells	NN	O	I-cell_line
with	NN	O	O
phorbol	NN	O	O
12-myristate	NN	O	O
13-acetate	NN	O	O
and	NN	O	O
ionomycin	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
FKBP	NN	O	B-RNA
mRNA	NN	O	I-RNA
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
enhancer	NN	O	B-DNA
elements	NN	O	I-DNA
in	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
highly	NN	O	O
conserved	NN	O	O
octamer	NN	O	B-DNA
(	NN	O	I-DNA
OCTA	NN	O	I-DNA
)	NN	O	I-DNA
-nucleotide	NN	O	I-DNA
motif	NN	O	I-DNA
are	NN	O	O
important	NN	O	O
for	NN	O	O
lymphoid-specific	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
immunoglobulin	NN	O	B-DNA
heavy-chain	NN	O	I-DNA
(	NN	O	I-DNA
IgH	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
we	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
mutating	NN	O	O
the	NN	O	O
binding	NN	O	B-DNA
site	NN	O	I-DNA
for	NN	O	O
a	NN	O	O
putative	NN	O	B-protein
additional	NN	O	I-protein
lymphoid-specific	NN	O	I-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
designated	NN	O	O
NF-microB	NN	O	B-protein
,	NN	O	O
in	NN	O	O
the	NN	O	O
murine	NN	O	B-DNA
IgH	NN	O	I-DNA
enhancer	NN	O	I-DNA
.	NN	O	O

While	NN	O	O
the	NN	O	O
HIV-2	NN	O	O
and	NN	O	O
HIV-1	NN	O	B-DNA
tat	NN	O	I-DNA
genes	NN	O	I-DNA
and	NN	O	O
T-cell	NN	O	B-protein
activators	NN	O	I-protein
apparently	NN	O	O
employ	NN	O	O
independent	NN	O	O
modes	NN	O	O
of	NN	O	O
action	NN	O	O
,	NN	O	O
the	NN	O	O
CMV	NN	O	B-DNA
transactivator	NN	O	I-DNA
in	NN	O	O
combination	NN	O	O
with	NN	O	O
the	NN	O	O
HIV-2	NN	O	B-DNA
tat	NN	O	I-DNA
or	NN	O	O
T-cell	NN	O	B-protein
activators	NN	O	I-protein
may	NN	O	O
employ	NN	O	O
a	NN	O	O
gene	NN	O	O
activation	NN	O	O
pathway	NN	O	O
with	NN	O	O
some	NN	O	O
common	NN	O	O
and	NN	O	O
some	NN	O	O
distinct	NN	O	O
components	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
proportion	NN	O	O
of	NN	O	O
transcripts	NN	O	B-RNA
appear	NN	O	O
to	NN	O	O
terminate	NN	O	O
prematurely	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
transactivators	NN	O	B-protein
.	NN	O	O

Quantitative	NN	O	O
immunohistochemical	NN	O	O
analysis	NN	O	O
of	NN	O	O
mononuclear	NN	O	B-cell_type
infiltrates	NN	O	I-cell_type
in	NN	O	O
breast	NN	O	O
carcinomas	NN	O	O
--	NN	O	O
correlation	NN	O	O
with	NN	O	O
tumour	NN	O	O
differentiation	NN	O	O
.	NN	O	O

A	NN	O	O
direct	NN	O	O
correlation	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
inflammation	NN	O	O
and	NN	O	O
nuclear	NN	O	O
grade	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.0001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
an	NN	O	O
inverse	NN	O	O
correlation	NN	O	O
between	NN	O	O
inflammation	NN	O	O
and	NN	O	O
oestrogen	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
OR	NN	O	B-protein
)	NN	O	O
positivity	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
inflammation	NN	O	O
and	NN	O	O
progesterone	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
PR	NN	O	B-protein
)	NN	O	O
positivity	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

GR	NN	O	O
binding	NN	O	O
characteristics	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
patients	NN	O	O
and	NN	O	O
controls	NN	O	O
or	NN	O	O
between	NN	O	O
patients	NN	O	O
subdivided	NN	O	O
according	NN	O	O
to	NN	O	O
diagnosis	NN	O	O
or	NN	O	O
associated	NN	O	O
clinical	NN	O	O
features	NN	O	O
.	NN	O	O

-DOCSTART-	O

Amplified	NN	O	O
c-erbB2	NN	O	B-DNA
gene	NN	O	I-DNA
sequences	NN	O	I-DNA
were	NN	O	O
present	NN	O	O
in	NN	O	O
21.5	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
samples	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
malignant	NN	O	O
cell	NN	O	O
cytokine	NN	O	B-protein
production	NN	O	O
may	NN	O	O
help	NN	O	O
explain	NN	O	O
this	NN	O	O
observation	NN	O	O
.	NN	O	O

The	NN	O	O
cells	NN	O	O
lines	NN	O	O
described	NN	O	O
here	NN	O	O
should	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
the	NN	O	O
delineation	NN	O	O
of	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
utilized	NN	O	O
in	NN	O	O
the	NN	O	O
selective	NN	O	O
regulation	NN	O	O
of	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
autoimmunity	NN	O	O
in	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
,	NN	O	O
evidence	NN	O	O
has	NN	O	O
been	NN	O	O
obtained	NN	O	O
further	NN	O	O
implicating	NN	O	O
the	NN	O	O
lymphokine	NN	O	B-protein
interferon-gamma	NN	O	B-protein
in	NN	O	O
the	NN	O	O
etiology	NN	O	O
of	NN	O	O
autoimmunity	NN	O	O
.	NN	O	O

Cloning	NN	O	O
of	NN	O	O
a	NN	O	O
transcriptionally	NN	O	B-protein
active	NN	O	I-protein
human	NN	O	I-protein
TATA	NN	O	I-protein
binding	NN	O	I-protein
factor	NN	O	I-protein
.	NN	O	O

The	NN	O	O
amino	NN	O	B-protein
terminus	NN	O	I-protein
contains	NN	O	O
an	NN	O	O
unusual	NN	O	O
repeat	NN	O	O
of	NN	O	O
38	NN	O	O
consecutive	NN	O	O
glutamine	NN	O	O
residues	NN	O	O
and	NN	O	O
an	NN	O	O
X-Thr-Pro	NN	O	B-protein
repeat	NN	O	I-protein
.	NN	O	O

Using	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
transfection	NN	O	O
,	NN	O	O
protein-DNA	NN	O	O
binding	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
transcription	NN	O	O
methods	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
discovered	NN	O	O
the	NN	O	O
novel	NN	O	B-protein
T-cell-specific	NN	O	I-protein
transcriptional	NN	O	I-protein
activator	NN	O	I-protein
TCF-1	NN	O	B-protein
(	NN	O	O
for	NN	O	O
T-Cell	NN	O	B-protein
Factor-1	NN	O	I-protein
)	NN	O	O
,	NN	O	O
which	NN	O	O
recognizes	NN	O	O
a	NN	O	O
T-cell-specific	NN	O	B-DNA
response	NN	O	I-DNA
element	NN	O	I-DNA
(	NN	O	O
TCE	NN	O	B-DNA
)	NN	O	O
located	NN	O	O
within	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Monofactorial	NN	O	O
analysis	NN	O	O
identified	NN	O	O
the	NN	O	O
following	NN	O	O
factors	NN	O	O
to	NN	O	O
be	NN	O	O
correlated	NN	O	O
with	NN	O	O
increased	NN	O	O
risk	NN	O	O
:	NN	O	O
moderate/marked	NN	O	O
mononuclear	NN	O	O
cell	NN	O	O
reaction	NN	O	O
(	NN	O	O
MCR	NN	O	O
)	NN	O	O
,	NN	O	O
high	NN	O	O
histologic	NN	O	O
grade	NN	O	O
(	NN	O	O
G	NN	O	O
)	NN	O	O
,	NN	O	O
extensive	NN	O	O
intraductal	NN	O	O
component	NN	O	O
(	NN	O	O
EIC	NN	O	O
)	NN	O	O
,	NN	O	O
tumor	NN	O	O
necrosis	NN	O	O
,	NN	O	O
macroscopic	NN	O	O
multiplicity	NN	O	O
,	NN	O	O
estrogen	NN	O	B-protein
receptor	NN	O	I-protein
negativity	NN	O	O
,	NN	O	O
anatomic	NN	O	O
tumor	NN	O	O
size	NN	O	O
,	NN	O	O
age	NN	O	O
younger	NN	O	O
than	NN	O	O
40	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
vascular	NN	O	O
invasion	NN	O	O
.	NN	O	O

The	NN	O	O
age	NN	O	O
dependence	NN	O	O
of	NN	O	O
morphologic	NN	O	O
risk	NN	O	O
factors	NN	O	O
appears	NN	O	O
to	NN	O	O
explain	NN	O	O
the	NN	O	O
high	NN	O	O
local	NN	O	O
failure	NN	O	O
rate	NN	O	O
seen	NN	O	O
in	NN	O	O
patients	NN	O	O
younger	NN	O	O
than	NN	O	O
40	NN	O	O
.	NN	O	O

-DOCSTART-	O

Two	NN	O	O
abundant	NN	O	O
proteins	NN	O	O
of	NN	O	O
75	NN	O	O
and	NN	O	O
80	NN	O	O
kD	NN	O	O
were	NN	O	O
competed	NN	O	O
out	NN	O	O
by	NN	O	O
poly	NN	O	O
[	NN	O	O
d	NN	O	O
(	NN	O	O
I-C	NN	O	O
)	NN	O	O
]	NN	O	O
in	NN	O	O
all	NN	O	O
reactions	NN	O	O
.	NN	O	O

This	NN	O	O
result	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
cAMP	NN	O	B-protein
response	NN	O	I-protein
element	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
,	NN	O	O
CREB	NN	O	B-protein
,	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
protein-TRE-DNA	NN	O	B-protein
complex	NN	O	I-protein
and	NN	O	O
in	NN	O	O
mediating	NN	O	O
the	NN	O	O
Tax	NN	O	B-protein
response	NN	O	O
.	NN	O	O

The	NN	O	O
complementary	NN	O	B-DNA
DNAs	NN	O	I-DNA
are	NN	O	O
the	NN	O	O
products	NN	O	O
of	NN	O	O
distinct	NN	O	O
genes	NN	O	O
,	NN	O	O
yet	NN	O	O
both	NN	O	O
ITF-1	NN	O	B-protein
and	NN	O	O
ITF-2	NN	O	B-protein
are	NN	O	O
structurally	NN	O	O
and	NN	O	O
functionally	NN	O	O
similar	NN	O	O
.	NN	O	O

-DOCSTART-	O

Elevated	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
concentrations	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
glucocorticoid	NN	O	O
therapy	NN	O	O
in	NN	O	O
peripheral	NN	O	B-cell_type
mononuclear	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
of	NN	O	O
patients	NN	O	O
with	NN	O	O
atopic	NN	O	O
dermatitis	NN	O	O
.	NN	O	O

The	NN	O	O
dissociation	NN	O	O
constant	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
methylprednisolone	NN	O	O
treatment	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
efficiency	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
in	NN	O	O
AD	NN	O	O
and	NN	O	O
findings	NN	O	O
of	NN	O	O
abnormal	NN	O	O
cAMP	NN	O	O
and	NN	O	O
cAMP-phosphodiesterase	NN	O	O
activity	NN	O	O
,	NN	O	O
the	NN	O	O
elevated	NN	O	O
GR	NN	O	B-protein
concentrations	NN	O	O
in	NN	O	O
AD	NN	O	O
lend	NN	O	O
support	NN	O	O
to	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
of	NN	O	O
a	NN	O	O
compensatory	NN	O	O
GR	NN	O	B-protein
upregulation	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
insufficient	NN	O	O
action	NN	O	O
of	NN	O	O
endogenous	NN	O	O
cortisol	NN	O	O
or	NN	O	O
to	NN	O	O
altered	NN	O	O
cAMP-induced	NN	O	O
GR	NN	O	B-protein
expression	NN	O	O
.	NN	O	O

-DOCSTART-	O

Using	NN	O	O
constructs	NN	O	O
in	NN	O	O
which	NN	O	O
mRNA	NN	O	B-RNA
production	NN	O	O
controlled	NN	O	O
by	NN	O	O
a	NN	O	O
specific	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
could	NN	O	O
be	NN	O	O
readily	NN	O	O
measured	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
both	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
and	NN	O	O
FK506	NN	O	O
completely	NN	O	O
inhibited	NN	O	O
transcription	NN	O	O
activated	NN	O	O
by	NN	O	O
NF-AT	NN	O	B-protein
,	NN	O	O
NFIL2	NN	O	B-protein
A	NN	O	I-protein
,	NN	O	O
NFIL2	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
partially	NN	O	O
inhibited	NN	O	O
transcription	NN	O	O
activated	NN	O	O
by	NN	O	O
NF	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
we	NN	O	O
did	NN	O	O
not	NN	O	O
observe	NN	O	O
any	NN	O	O
qualitative	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
and	NN	O	O
FK506	NN	O	O
on	NN	O	O
six	NN	O	O
different	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
which	NN	O	O
suggests	NN	O	O
that	NN	O	O
these	NN	O	O
drugs	NN	O	O
may	NN	O	O
interfere	NN	O	O
with	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
Ca2+	NN	O	O
dependent	NN	O	O
step	NN	O	O
that	NN	O	O
regulates	NN	O	O
several	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

The	NN	O	O
rex	NN	O	B-DNA
gene	NN	O	I-DNA
encodes	NN	O	O
two	NN	O	O
protein	NN	O	O
products	NN	O	O
,	NN	O	O
p27rex/p21rex	NN	O	B-protein
and	NN	O	O
p26rex/p24rex	NN	O	B-protein
in	NN	O	O
HTLV-I	NN	O	O
and	NN	O	O
HTLV-II	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
importance	NN	O	O
of	NN	O	O
the	NN	O	O
internal	NN	O	O
ATGs	NN	O	O
to	NN	O	O
Rex	NN	O	B-protein
function	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

The	NN	O	O
'octamer	NN	O	B-DNA
'	NN	O	I-DNA
sequence	NN	O	I-DNA
,	NN	O	O
ATGCAAAT	NN	O	O
or	NN	O	O
its	NN	O	O
complement	NN	O	O
ATTTGCAT	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
key	NN	O	O
element	NN	O	O
for	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
regulation	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
B-lymphocytes	NN	O	B-cell_type
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
housekeeping	NN	O	B-DNA
genes	NN	O	I-DNA
in	NN	O	O
all	NN	O	O
cell	NN	O	O
types	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
these	NN	O	O
assays	NN	O	O
,	NN	O	O
all	NN	O	O
N-Oct-factors	NN	O	B-protein
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
distinct	NN	O	O
from	NN	O	O
the	NN	O	O
ubiquitous	NN	O	B-protein
Oct-1	NN	O	I-protein
and	NN	O	O
the	NN	O	O
lymphoid-specific	NN	O	B-protein
Oct-2A	NN	O	I-protein
proteins	NN	O	O
.	NN	O	O

-DOCSTART-	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
Rex	NN	O	B-protein
is	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
viral	NN	O	O
RNA	NN	O	O
partition	NN	O	O
of	NN	O	O
HTLV-I	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
CD4	NN	O	B-protein
,	NN	O	O
a	NN	O	O
marker	NN	O	O
for	NN	O	O
T-derived	NN	O	B-cell_type
lymphoid	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
in	NN	O	O
serum-free	NN	O	O
medium	NN	O	O
.	NN	O	O

GCR	NN	O	B-protein
on	NN	O	O
MNL	NN	O	B-cell_type
,	NN	O	O
PML	NN	O	B-cell_type
and	NN	O	O
mixed	NN	O	B-cell_type
leucocytes	NN	O	I-cell_type
in	NN	O	O
5	NN	O	O
patients	NN	O	O
were	NN	O	O
determined	NN	O	O
simultaneously	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
lowered	NN	O	O
from	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Plasma	NN	O	B-protein
renin	NN	O	I-protein
activity	NN	O	O
and	NN	O	O
aldosterone	NN	O	O
were	NN	O	O
not	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
electrolyte	NN	O	O
response	NN	O	O
and	NN	O	O
were	NN	O	O
within	NN	O	O
the	NN	O	O
normal	NN	O	O
limits	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
mineralocorticoid	NN	O	B-protein
receptors	NN	O	I-protein
/cell	NN	O	O
were	NN	O	O
within	NN	O	O
or	NN	O	O
close	NN	O	O
to	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
provide	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
studying	NN	O	O
1	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3	NN	O	O
(	NN	O	O
calcitriol	NN	O	O
)	NN	O	O
in	NN	O	O
lymphocytes	NN	O	B-cell_type
of	NN	O	O
children	NN	O	O
with	NN	O	O
rickets	NN	O	O
and	NN	O	O
rickets-like	NN	O	O
diseases	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
proposed	NN	O	O
that	NN	O	O
the	NN	O	O
character	NN	O	O
of	NN	O	O
their	NN	O	O
expression	NN	O	O
under	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
differential	NN	O	O
diagnostic	NN	O	O
purposes	NN	O	O
in	NN	O	O
view	NN	O	O
.	NN	O	O

The	NN	O	O
modified	NN	O	O
oligonucleotides	NN	O	O
accumulated	NN	O	O
in	NN	O	O
cells	NN	O	O
more	NN	O	O
effectively	NN	O	O
than	NN	O	O
standard	NN	O	O
ds	NN	O	O
oligonucleotides	NN	O	O
and	NN	O	O
modulated	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
a	NN	O	O
specific	NN	O	O
manner	NN	O	O
.	NN	O	O

The	NN	O	O
ds	NN	O	O
phosphorothioate	NN	O	O
oligonucleotides	NN	O	O
probably	NN	O	O
compete	NN	O	O
for	NN	O	O
binding	NN	O	O
of	NN	O	O
specific	NN	O	O
transcription	NN	O	O
factors	NN	O	O
and	NN	O	O
may	NN	O	O
provide	NN	O	O
anti-viral	NN	O	O
,	NN	O	O
immunosuppressive	NN	O	O
,	NN	O	O
or	NN	O	O
other	NN	O	O
therapeutic	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
concentration	NN	O	O
and	NN	O	O
the	NN	O	O
sites	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
(	NN	O	O
GCR	NN	O	B-protein
)	NN	O	O
in	NN	O	O
the	NN	O	O
peripheral	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
were	NN	O	O
measured	NN	O	O
in	NN	O	O
32	NN	O	O
healthy	NN	O	O
aged	NN	O	O
persons	NN	O	O
and	NN	O	O
13	NN	O	O
young	NN	O	O
adults	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
GCR	NN	O	B-protein
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
aged	NN	O	O
persons	NN	O	O
or	NN	O	O
rats	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
young	NN	O	O
while	NN	O	O
the	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
level	NN	O	O
did	NN	O	O
n't	NN	O	O
change	NN	O	O
with	NN	O	O
aging	NN	O	O
.	NN	O	O

So	NN	O	O
we	NN	O	O
think	NN	O	O
that	NN	O	O
GCR	NN	O	B-protein
is	NN	O	O
more	NN	O	O
sensitive	NN	O	O
than	NN	O	O
the	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
level	NN	O	O
to	NN	O	O
reflect	NN	O	O
the	NN	O	O
aging	NN	O	O
change	NN	O	O
of	NN	O	O
the	NN	O	O
adrenal	NN	O	O
cortex	NN	O	O
function	NN	O	O
.	NN	O	O

-DOCSTART-	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
IFN-alpha	NN	O	B-protein
in	NN	O	O
CML	NN	O	O
may	NN	O	O
be	NN	O	O
linked	NN	O	O
to	NN	O	O
a	NN	O	O
pathway	NN	O	O
that	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
posttranslational	NN	O	O
modification	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

(	NN	O	O
v	NN	O	O
)	NN	O	O
An	NN	O	O
EBNA-2-responsive	NN	O	B-DNA
element	NN	O	I-DNA
was	NN	O	O
found	NN	O	O
within	NN	O	O
the	NN	O	O
-512	NN	O	B-DNA
to	NN	O	I-DNA
+40	NN	O	I-DNA
LMP1	NN	O	I-DNA
DNA	NN	O	I-DNA
since	NN	O	O
this	NN	O	O
DNA	NN	O	O
linked	NN	O	O
to	NN	O	O
a	NN	O	O
chloramphenicol	NN	O	B-DNA
acetyltransferase	NN	O	I-DNA
reporter	NN	O	I-DNA
gene	NN	O	I-DNA
was	NN	O	O
transactivated	NN	O	O
by	NN	O	O
cotransfection	NN	O	O
with	NN	O	O
an	NN	O	O
EBNA-2	NN	O	B-DNA
expression	NN	O	I-DNA
vector	NN	O	I-DNA
.	NN	O	O

(	NN	O	O
vi	NN	O	O
)	NN	O	O
The	NN	O	O
EBV	NN	O	O
type	NN	O	O
2	NN	O	O
EBNA-2	NN	O	B-protein
transactivated	NN	O	O
LMP1	NN	O	B-protein
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
EBV	NN	O	B-protein
type	NN	O	I-protein
1	NN	O	I-protein
EBNA-2	NN	O	I-protein
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
EBNA-2	NN	O	B-protein
transactivation	NN	O	O
of	NN	O	O
LMP1	NN	O	B-protein
amplifies	NN	O	O
the	NN	O	O
biological	NN	O	O
impact	NN	O	O
of	NN	O	O
EBNA-2	NN	O	B-protein
and	NN	O	O
underscores	NN	O	O
its	NN	O	O
central	NN	O	O
role	NN	O	O
in	NN	O	O
EBV-induced	NN	O	O
growth	NN	O	O
transformation	NN	O	O
.	NN	O	O

Anti-	NN	O	O
HBx	NN	O	B-protein
antibody	NN	O	O
titers	NN	O	O
as	NN	O	O
revealed	NN	O	O
by	NN	O	O
peptide	NN	O	O
ELISAs	NN	O	O
were	NN	O	O
highest	NN	O	O
and	NN	O	O
most	NN	O	O
frequent	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
hepatitis	NN	O	O
and	NN	O	O
usually	NN	O	O
low	NN	O	O
in	NN	O	O
acutely	NN	O	O
infected	NN	O	O
patients	NN	O	O
and	NN	O	O
asymptomatic	NN	O	O
carriers	NN	O	O
.	NN	O	O

Such	NN	O	O
tests	NN	O	O
may	NN	O	O
become	NN	O	O
useful	NN	O	O
diagnostic	NN	O	O
tools	NN	O	O
.	NN	O	O

Both	NN	O	O
RM	NN	O	O
and	NN	O	O
ChtM	NN	O	O
showed	NN	O	O
circadian	NN	O	O
rhythm	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
glucocorticoids	NN	O	O
(	NN	O	O
GC	NN	O	O
)	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
physiological	NN	O	O
regulator	NN	O	O
of	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
leukocytes	NN	O	B-cell_type
and	NN	O	O
its	NN	O	O
inhibitory	NN	O	O
action	NN	O	O
on	NN	O	O
ChtM	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
antiinflammatory	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
GC	NN	O	O
of	NN	O	O
pharmacological	NN	O	O
doses	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
two	NN	O	O
proteins	NN	O	O
differ	NN	O	O
in	NN	O	O
their	NN	O	O
surface	NN	O	O
charge	NN	O	O
,	NN	O	O
since	NN	O	O
they	NN	O	O
are	NN	O	O
separable	NN	O	O
by	NN	O	O
anion-exchange	NN	O	O
chromatography	NN	O	O
.	NN	O	O

Both	NN	O	O
C1	NN	O	B-protein
and	NN	O	O
C2	NN	O	B-protein
proteins	NN	O	I-protein
also	NN	O	O
bind	NN	O	O
to	NN	O	O
a	NN	O	O
similar	NN	O	O
sequence	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
interleukin-2-receptor	NN	O	B-DNA
alpha-subunit	NN	O	I-DNA
enhancer	NN	O	I-DNA
.	NN	O	O

Several	NN	O	O
new	NN	O	O
4	NN	O	O
,	NN	O	O
19-substituted	NN	O	O
steroids	NN	O	O
and	NN	O	O
previously	NN	O	O
synthesized	NN	O	O
corticosteroids	NN	O	O
were	NN	O	O
assayed	NN	O	O
for	NN	O	O
affinity	NN	O	O
to	NN	O	O
type	NN	O	B-protein
1	NN	O	I-protein
receptors	NN	O	I-protein
in	NN	O	O
human	NN	O	B-cell_type
mononuclear	NN	O	I-cell_type
leukocytes	NN	O	I-cell_type
.	NN	O	O

For	NN	O	O
comparison	NN	O	O
,	NN	O	O
other	NN	O	O
RBA	NN	O	O
in	NN	O	O
this	NN	O	O
system	NN	O	O
were	NN	O	O
:	NN	O	O
19-noraldosterone	NN	O	O
,	NN	O	O
20	NN	O	O
%	NN	O	O
;	NN	O	O
18-deoxyaldosterone	NN	O	O
,	NN	O	O
5.8	NN	O	O
%	NN	O	O
;	NN	O	O
18-deoxy-19-noraldosterone	NN	O	O
,	NN	O	O
4.7	NN	O	O
%	NN	O	O
;	NN	O	O
18	NN	O	O
,	NN	O	O
21-anhydroaldosterone	NN	O	O
,	NN	O	O
0.37	NN	O	O
%	NN	O	O
;	NN	O	O
17-isoaldosterone	NN	O	O
,	NN	O	O
7.6	NN	O	O
%	NN	O	O
and	NN	O	O
apoaldosterone	NN	O	O
,	NN	O	O
4.3	NN	O	O
%	NN	O	O

Cell	NN	O	O
type	NN	O	O
specificity	NN	O	O
and	NN	O	O
activation	NN	O	O
requirements	NN	O	O
for	NN	O	O
NFAT-1	NN	O	B-protein
(	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
of	NN	O	O
activated	NN	O	B-cell_type
T-cells	NN	O	I-cell_type
)	NN	O	O
transcriptional	NN	O	O
activity	NN	O	O
determined	NN	O	O
by	NN	O	O
a	NN	O	O
new	NN	O	O
method	NN	O	O
using	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
to	NN	O	O
assay	NN	O	O
transcriptional	NN	O	O
activity	NN	O	O
of	NN	O	O
an	NN	O	O
individual	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
the	NN	O	O
tissue	NN	O	O
pattern	NN	O	O
of	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
NFAT-1	NN	O	B-protein
activity	NN	O	O
resembles	NN	O	O
the	NN	O	O
expression	NN	O	O
pattern	NN	O	O
described	NN	O	O
for	NN	O	O
HIV-LTR/tat	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
(	NN	O	O
Vogel	NN	O	O
,	NN	O	O
J.	NN	O	O
,	NN	O	O
Hinrichs	NN	O	O
,	NN	O	O
S.	NN	O	O
H.	NN	O	O
,	NN	O	O
Reynolds	NN	O	O
,	NN	O	O
R.	NN	O	O
K.	NN	O	O
,	NN	O	O
Luciw	NN	O	O
,	NN	O	O
P.	NN	O	O
A.	NN	O	O
,	NN	O	O
and	NN	O	O
Jay	NN	O	O
,	NN	O	O
G.	NN	O	O
(	NN	O	O
1988	NN	O	O
)	NN	O	O
Nature	NN	O	O
335	NN	O	O
,	NN	O	O
606-611	NN	O	O
)	NN	O	O
.	NN	O	O

-DOCSTART-	O

A	NN	O	O
7-base-pair	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
site	NN	O	B-DNA
B	NN	O	I-DNA
palindrome	NN	O	I-DNA
,	NN	O	O
which	NN	O	O
destroyed	NN	O	O
protein	NN	O	O
binding	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
increased	NN	O	O
expression	NN	O	O
from	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
1	NN	O	I-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
in	NN	O	O
T	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
56-59-kilodalton	NN	O	B-protein
protein	NN	O	I-protein
identified	NN	O	O
in	NN	O	O
untransformed	NN	O	B-protein
steroid	NN	O	I-protein
receptor	NN	O	I-protein
complexes	NN	O	I-protein
is	NN	O	O
a	NN	O	O
unique	NN	O	B-protein
protein	NN	O	I-protein
that	NN	O	O
exists	NN	O	O
in	NN	O	O
cytosol	NN	O	O
in	NN	O	O
a	NN	O	O
complex	NN	O	O
with	NN	O	O
both	NN	O	O
the	NN	O	O
70-	NN	O	B-protein
and	NN	O	I-protein
90-kilodalton	NN	O	I-protein
heat	NN	O	I-protein
shock	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

Neither	NN	O	O
heat	NN	O	B-protein
shock	NN	O	I-protein
protein	NN	O	I-protein
reacts	NN	O	O
directly	NN	O	O
with	NN	O	O
the	NN	O	O
EC1	NN	O	B-protein
antibody	NN	O	I-protein
.	NN	O	O

Sequence-specific	NN	O	O
DNA	NN	O	O
binding	NN	O	O
of	NN	O	O
the	NN	O	O
proto-oncoprotein	NN	O	B-protein
ets-1	NN	O	B-protein
defines	NN	O	O
a	NN	O	O
transcriptional	NN	O	B-DNA
activator	NN	O	I-DNA
sequence	NN	O	I-DNA
within	NN	O	O
the	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
Moloney	NN	O	O
murine	NN	O	O
sarcoma	NN	O	O
virus	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
ets-1	NN	O	B-protein
functions	NN	O	O
as	NN	O	O
a	NN	O	O
transcriptional	NN	O	O
activator	NN	O	O
of	NN	O	O
mammalian	NN	O	O
type-C	NN	O	O
retroviruses	NN	O	O
and	NN	O	O
speculate	NN	O	O
that	NN	O	O
ets-related	NN	O	B-DNA
genes	NN	O	I-DNA
constitute	NN	O	O
a	NN	O	O
new	NN	O	O
group	NN	O	O
of	NN	O	O
eukaryotic	NN	O	B-protein
DNA-binding	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

-DOCSTART-	O

BSAP	NN	O	B-protein
:	NN	O	O
a	NN	O	O
key	NN	O	O
regulator	NN	O	O
of	NN	O	O
B-cell	NN	O	B-cell_type
development	NN	O	O
and	NN	O	O
differentiation	NN	O	O
.	NN	O	O

Besides	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
decreased	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
another	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
protein	NN	O	I-protein
,	NN	O	O
namely	NN	O	O
c-rel	NN	O	B-protein
.	NN	O	O

These	NN	O	O
observations	NN	O	O
demonstrate	NN	O	O
directly	NN	O	O
that	NN	O	O
there	NN	O	O
is	NN	O	O
de	NN	O	O
novo	NN	O	O
synthesis	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
during	NN	O	O
human	NN	O	O
lymphocyte	NN	O	O
activation	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
this	NN	O	O
process	NN	O	O
is	NN	O	O
hormonally	NN	O	O
regulated	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
MZF-1	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
are	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
promoters	NN	O	B-DNA
of	NN	O	O
several	NN	O	O
genes	NN	O	B-DNA
expressed	NN	O	O
during	NN	O	O
myeloid	NN	O	O
differentiation	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
CD34	NN	O	B-DNA
promoter	NN	O	I-DNA
.	NN	O	O

Recombinant	NN	O	B-protein
MZF-1	NN	O	I-protein
protein	NN	O	I-protein
specifically	NN	O	O
binds	NN	O	O
to	NN	O	O
the	NN	O	O
consensus	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
CD34	NN	O	B-DNA
promoter	NN	O	I-DNA
in	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assays	NN	O	O
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
CD34	NN	O	B-protein
expression	NN	O	O
in	NN	O	O
hematopoietic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
is	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
intact	NN	O	O
MZF-1	NN	O	B-DNA
binding	NN	O	I-DNA
sites	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
murine	NN	O	O
BCL6	NN	O	B-DNA
gene	NN	O	I-DNA
is	NN	O	O
induced	NN	O	O
in	NN	O	O
activated	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
as	NN	O	O
an	NN	O	O
immediate	NN	O	B-DNA
early	NN	O	I-DNA
gene	NN	O	I-DNA
.	NN	O	O

This	NN	O	O
induction	NN	O	O
was	NN	O	O
not	NN	O	O
inhibited	NN	O	O
by	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
with	NN	O	O
a	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
cycloheximide	NN	O	O
.	NN	O	O

Other	NN	O	O
experimental	NN	O	O
strategies	NN	O	O
have	NN	O	O
implicated	NN	O	O
BSAP	NN	O	B-protein
in	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
,	NN	O	O
isotype	NN	O	O
switching	NN	O	O
and	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
immunoglobulin	NN	O	B-protein
heavy-chain	NN	O	I-protein
gene	NN	O	O
at	NN	O	O
late	NN	O	O
stages	NN	O	O
of	NN	O	O
B-cell	NN	O	O
differentiation	NN	O	O
.	NN	O	O

-DOCSTART-	O

Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
biochemical	NN	O	O
and	NN	O	O
cell	NN	O	O
biological	NN	O	O
properties	NN	O	O
of	NN	O	O
these	NN	O	O
HSFs	NN	O	B-protein
reveals	NN	O	O
that	NN	O	O
HSF3	NN	O	B-protein
has	NN	O	O
properties	NN	O	O
in	NN	O	O
common	NN	O	O
with	NN	O	O
both	NN	O	O
HSF1	NN	O	B-protein
and	NN	O	O
HSF2	NN	O	B-protein
and	NN	O	O
yet	NN	O	O
has	NN	O	O
features	NN	O	O
which	NN	O	O
are	NN	O	O
distinct	NN	O	O
from	NN	O	O
both	NN	O	O
.	NN	O	O

HSF3	NN	O	B-protein
is	NN	O	O
constitutively	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
erythroblast	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
HD6	NN	O	I-cell_line
,	NN	O	O
the	NN	O	O
lymphoblast	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
MSB	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
embryo	NN	O	B-cell_line
fibroblasts	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
yet	NN	O	O
its	NN	O	O
DNA-binding	NN	O	O
activity	NN	O	O
is	NN	O	O
induced	NN	O	O
only	NN	O	O
upon	NN	O	O
exposure	NN	O	O
of	NN	O	O
HD6	NN	O	O
cells	NN	O	O
to	NN	O	O
heat	NN	O	O
shock	NN	O	O
.	NN	O	O

NFATp	NN	O	B-protein
immunoprecipitated	NN	O	O
from	NN	O	O
32P-labeled	NN	O	B-cell_line
HT-2	NN	O	I-cell_line
cells	NN	O	I-cell_line
migrated	NN	O	O
as	NN	O	O
an	NN	O	O
approximately	NN	O	O
120-kDa	NN	O	O
protein	NN	O	O
that	NN	O	O
was	NN	O	O
localized	NN	O	O
to	NN	O	O
the	NN	O	O
cytosol	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
dephosphorylation	NN	O	O
of	NN	O	O
NFATp	NN	O	B-protein
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
localization	NN	O	O
of	NN	O	O
the	NN	O	O
protein	NN	O	O
to	NN	O	O
the	NN	O	O
nuclear	NN	O	O
fraction	NN	O	O
.	NN	O	O

Activation	NN	O	O
and	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
factors	NN	O	I-protein
of	NN	O	O
activated	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
NFATp	NN	O	B-protein
and	NN	O	O
NFATc	NN	O	B-protein
,	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
natural	NN	O	I-cell_type
killer	NN	O	I-cell_type
cells	NN	O	I-cell_type
:	NN	O	O
regulation	NN	O	O
upon	NN	O	O
CD16	NN	O	B-protein
ligand	NN	O	O
binding	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
important	NN	O	O
cytokines	NN	O	B-protein
involved	NN	O	O
in	NN	O	O
immune	NN	O	O
response	NN	O	O
regulation	NN	O	O
is	NN	O	O
interleukin	NN	O	O
2	NN	O	O
(	NN	O	O
IL-2	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
activator	NN	O	O
of	NN	O	O
the	NN	O	O
proliferation	NN	O	O
and	NN	O	O
function	NN	O	O
of	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
and	NN	O	O
natural	NN	O	B-cell_type
killer	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
monocyte	NN	O	O
and	NN	O	O
lymphocyte	NN	O	O
counts	NN	O	O
and	NN	O	O
the	NN	O	O
blood	NN	O	O
estrogen	NN	O	O
levels	NN	O	O
of	NN	O	O
each	NN	O	O
patient	NN	O	O
were	NN	O	O
determine	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
During	NN	O	O
menopause	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
ER	NN	O	B-cell_type
positive	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
blood	NN	O	B-cell_type
monocyte	NN	O	I-cell_type
number	NN	O	O
,	NN	O	O
which	NN	O	O
declines	NN	O	O
following	NN	O	O
estrogen	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
to	NN	O	O
values	NN	O	O
of	NN	O	O
the	NN	O	O
young	NN	O	O
.	NN	O	O

The	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
composition	NN	O	O
of	NN	O	O
IL-2Rs	NN	O	B-protein
were	NN	O	O
accompanied	NN	O	O
by	NN	O	O
inhibition	NN	O	O
of	NN	O	O
IL-2	NN	O	B-protein
-induced	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
the	NN	O	O
Janus	NN	O	B-protein
protein-tyrosine	NN	O	I-protein
kinase	NN	O	I-protein
3	NN	O	I-protein
(	NN	O	O
Jak3	NN	O	B-protein
)	NN	O	O
and	NN	O	O
signal	NN	O	B-protein
transducers	NN	O	I-protein
and	NN	O	I-protein
activators	NN	O	I-protein
of	NN	O	I-protein
transcription	NN	O	I-protein
called	NN	O	O
Stat3	NN	O	B-protein
and	NN	O	O
Stat5	NN	O	B-protein
.	NN	O	O

In	NN	O	O
parallel	NN	O	O
experiments	NN	O	O
,	NN	O	O
IL-2	NN	O	B-protein
-driven	NN	O	O
proliferation	NN	O	O
was	NN	O	O
inhibited	NN	O	O
significantly	NN	O	O
.	NN	O	O

Apparently	NN	O	O
normal	NN	O	O
at	NN	O	O
birth	NN	O	O
,	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
-/-	NN	O	O
mice	NN	O	O
exhibit	NN	O	O
severe	NN	O	O
runting	NN	O	O
,	NN	O	O
skin	NN	O	O
defects	NN	O	O
,	NN	O	O
and	NN	O	O
extensive	NN	O	O
granulopoiesis	NN	O	O
postnatally	NN	O	O
,	NN	O	O
typically	NN	O	O
dying	NN	O	O
by	NN	O	O
8	NN	O	O
days	NN	O	O
.	NN	O	O

IL-7	NN	O	B-protein
was	NN	O	O
observed	NN	O	O
to	NN	O	O
induce	NN	O	O
a	NN	O	O
rapid	NN	O	O
and	NN	O	O
dose-dependent	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
Jak	NN	O	B-protein
1	NN	O	I-protein
and	NN	O	O
Jak	NN	O	B-protein
3	NN	O	I-protein
and	NN	O	O
concomitantly	NN	O	O
,	NN	O	O
the	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
DNA	NN	O	O
binding	NN	O	O
activity	NN	O	O
of	NN	O	O
multiple	NN	O	O
STAT	NN	O	B-protein
proteins	NN	O	I-protein
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
it	NN	O	O
inhibited	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
LTB4	NN	O	B-protein
(	NN	O	O
IC50	NN	O	O
=	NN	O	O
0.5	NN	O	O
microM	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
cytokines	NN	O	B-protein
IL-2	NN	O	B-protein
,	NN	O	O
IL-6	NN	O	B-protein
and	NN	O	O
TNF	NN	O	B-protein
alpha	NN	O	I-protein
(	NN	O	O
IC50	NN	O	O
=	NN	O	O
10-12	NN	O	O
microM	NN	O	O
)	NN	O	O
.	NN	O	O

Tepoxalin	NN	O	O
also	NN	O	O
inhibits	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
NF	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
,	NN	O	O
a	NN	O	O
transcription	NN	O	B-protein
factor	NN	O	I-protein
which	NN	O	O
acts	NN	O	O
on	NN	O	O
several	NN	O	O
cytokine	NN	O	B-DNA
genes	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
with	NN	O	O
the	NN	O	O
proteasome	NN	O	B-protein
inhibitor	NN	O	O
N-Ac-Leu-Leu-norleucinal	NN	O	O
inhibits	NN	O	O
this	NN	O	O
ligand-induced	NN	O	O
degradation	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
agreement	NN	O	O
with	NN	O	O
previous	NN	O	O
studies	NN	O	O
,	NN	O	O
stabilizes	NN	O	O
a	NN	O	O
hyperphosphorylated	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	B-protein
I	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
protein	NN	O	I-protein
.	NN	O	O

By	NN	O	O
expressing	NN	O	O
mutant	NN	O	O
forms	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
protein	NN	O	O
in	NN	O	O
this	NN	O	O
cell	NN	O	B-cell_line
line	NN	O	I-cell_line
,	NN	O	O
we	NN	O	O
have	NN	O	O
been	NN	O	O
able	NN	O	O
to	NN	O	O
delineate	NN	O	O
the	NN	O	O
sequences	NN	O	O
responsible	NN	O	O
for	NN	O	O
both	NN	O	O
the	NN	O	O
ligand-induced	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
the	NN	O	O
degradation	NN	O	O
of	NN	O	O
I	NN	O	B-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
alpha	NN	O	I-protein
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
Rap1	NN	O	B-protein
protein	NN	O	I-protein
was	NN	O	O
differentially	NN	O	O
phosphorylated	NN	O	O
when	NN	O	O
using	NN	O	O
15	NN	O	O
micrograms/ml	NN	O	O
of	NN	O	O
the	NN	O	O
C.	NN	O	B-protein
Sub	NN	O	I-protein
.	NN	O	I-protein

An	NN	O	O
IRF-1	NN	O	B-protein
-dependent	NN	O	O
pathway	NN	O	O
of	NN	O	O
DNA	NN	O	O
damage-induced	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
mitogen-activated	NN	O	B-cell_line
T	NN	O	I-cell_line
lymphocytes	NN	O	I-cell_line
.	NN	O	O

Thus	NN	O	O
two	NN	O	O
different	NN	O	O
anti-onco-genic	NN	O	B-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
,	NN	O	O
p53	NN	O	B-protein
and	NN	O	O
IRF-1	NN	O	B-protein
,	NN	O	O
are	NN	O	O
required	NN	O	O
for	NN	O	O
distinct	NN	O	O
apoptotic	NN	O	O
pathways	NN	O	O
in	NN	O	O
T	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
difference	NN	O	O
between	NN	O	O
them	NN	O	O
was	NN	O	O
significant	NN	O	O
statistically	NN	O	O
.	NN	O	O

2	NN	O	O
)	NN	O	O
The	NN	O	O
FI	NN	O	O
of	NN	O	O
the	NN	O	O
chemotactic	NN	O	O
migration	NN	O	O
rate	NN	O	O
of	NN	O	O
PMN	NN	O	B-cell_type
by	NN	O	O
cortisol	NN	O	O
also	NN	O	O
showed	NN	O	O
diurnal	NN	O	O
changes	NN	O	O
which	NN	O	O
were	NN	O	O
synchronous	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
GR	NN	O	B-protein
.	NN	O	O

Coexpression	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B/Rel	NN	O	I-protein
and	NN	O	O
Sp1	NN	O	B-protein
transcription	NN	O	B-protein
factors	NN	O	I-protein
in	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
1-induced	NN	O	O
,	NN	O	O
dendritic	NN	O	O
cell-T-cell	NN	O	O
syncytia	NN	O	O
.	NN	O	O

DCs	NN	O	B-cell_type
express	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
all	NN	O	O
known	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
and	NN	O	O
Rel	NN	O	B-protein
proteins	NN	O	I-protein
,	NN	O	O
with	NN	O	O
activity	NN	O	O
residing	NN	O	O
primarily	NN	O	O
within	NN	O	O
RelB	NN	O	B-protein
,	NN	O	O
p50	NN	O	B-protein
,	NN	O	O
and	NN	O	O
p65	NN	O	B-protein
.	NN	O	O

Cloning	NN	O	O
a	NN	O	O
cDNA	NN	O	B-DNA
from	NN	O	O
human	NN	O	O
NK/T	NN	O	B-cell_type
cells	NN	O	I-cell_type
which	NN	O	O
codes	NN	O	O
for	NN	O	O
a	NN	O	O
protein	NN	O	O
with	NN	O	O
high	NN	O	O
proline	NN	O	O
content	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
B4-2	NN	O	B-DNA
has	NN	O	O
an	NN	O	O
unusually	NN	O	O
high	NN	O	O
proline	NN	O	O
content	NN	O	O
(	NN	O	O
13	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
contains	NN	O	O
a	NN	O	O
putative	NN	O	O
nuclear	NN	O	B-protein
targeting	NN	O	I-protein
sequence	NN	O	I-protein
,	NN	O	O
and	NN	O	O
has	NN	O	O
several	NN	O	O
SPXX	NN	O	B-protein
motifs	NN	O	I-protein
which	NN	O	O
are	NN	O	O
frequently	NN	O	O
found	NN	O	O
in	NN	O	O
gene	NN	O	B-protein
regulatory	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

Northern	NN	O	O
hybridization	NN	O	O
data	NN	O	O
showed	NN	O	O
that	NN	O	O
B4-2	NN	O	B-DNA
is	NN	O	O
not	NN	O	O
a	NN	O	O
lymphoid	NN	O	B-DNA
specific	NN	O	I-DNA
gene	NN	O	I-DNA
and	NN	O	O
is	NN	O	O
expressed	NN	O	O
in	NN	O	O
a	NN	O	O
hepatoma	NN	O	B-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
and	NN	O	O
also	NN	O	O
weakly	NN	O	O
transcribed	NN	O	O
or	NN	O	O
absent	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
other	NN	O	O
cells	NN	O	O
.	NN	O	O

A	NN	O	O
polyclonal	NN	O	O
antiserum	NN	O	O
raised	NN	O	O
against	NN	O	O
recombinant	NN	O	B-protein
B4-2	NN	O	I-protein
recognizes	NN	O	O
a	NN	O	O
32-34	NN	O	B-protein
kDa	NN	O	I-protein
protein	NN	O	I-protein
in	NN	O	O
lymphocytes	NN	O	B-cell_type
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
when	NN	O	O
human	NN	O	B-protein
IL-2R	NN	O	I-protein
beta	NN	O	I-protein
was	NN	O	O
stably	NN	O	O
expressed	NN	O	O
in	NN	O	O
murine	NN	O	B-cell_line
BA/F3	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
robust	NN	O	O
IL-2	NN	O	B-protein
-induced	NN	O	O
proliferation	NN	O	O
and	NN	O	O
JAK3	NN	O	B-protein
activation	NN	O	O
occurred	NN	O	O
without	NN	O	O
detectable	NN	O	O
involvement	NN	O	O
of	NN	O	O
either	NN	O	O
JAK1	NN	O	B-protein
,	NN	O	O
JAK2	NN	O	B-protein
or	NN	O	O
TYK2	NN	O	B-protein
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
propose	NN	O	O
that	NN	O	O
IL-2	NN	O	B-protein
receptor	NN	O	I-protein
signal	NN	O	O
transduction	NN	O	O
does	NN	O	O
not	NN	O	O
depend	NN	O	O
on	NN	O	O
equimolar	NN	O	O
heterodimerization	NN	O	O
of	NN	O	O
JAK1	NN	O	B-protein
and	NN	O	O
JAK3	NN	O	B-protein
following	NN	O	O
IL-2	NN	O	B-protein
-induced	NN	O	O
heterodimerization	NN	O	O
of	NN	O	O
IL-2R	NN	O	B-protein
beta	NN	O	I-protein
and	NN	O	O
IL-2R	NN	O	B-protein
gamma	NN	O	I-protein
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
STAT5	NN	O	B-protein
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
predominant	NN	O	O
STAT	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
used	NN	O	O
by	NN	O	O
IL-2	NN	O	B-protein
in	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
and	NN	O	O
specifically	NN	O	O
required	NN	O	O
a	NN	O	O
COOH-terminal	NN	O	B-protein
region	NN	O	I-protein
of	NN	O	O
IL-2R	NN	O	B-protein
beta	NN	O	I-protein
(	NN	O	O
Ser386-Val525	NN	O	B-protein
)	NN	O	O
,	NN	O	O
while	NN	O	O
STAT5	NN	O	B-protein
recruitment	NN	O	O
was	NN	O	O
not	NN	O	O
correlated	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
IL-2R	NN	O	B-protein
gamma	NN	O	I-protein
or	NN	O	O
JAK3	NN	O	B-protein
.	NN	O	O

p50	NN	O	B-protein
is	NN	O	O
translated	NN	O	O
as	NN	O	O
a	NN	O	O
precursor	NN	O	O
of	NN	O	O
105	NN	O	B-protein
kDa	NN	O	I-protein
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
demonstrate	NN	O	O
reconstitution	NN	O	O
of	NN	O	O
a	NN	O	O
cell-free	NN	O	O
processing	NN	O	O
system	NN	O	O
and	NN	O	O
demonstrate	NN	O	O
directly	NN	O	O
that	NN	O	O
:	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
the	NN	O	O
ubiquitin	NN	O	B-protein
-proteasome	NN	O	B-protein
system	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
processing	NN	O	O
of	NN	O	O
the	NN	O	O
intact	NN	O	O
p105	NN	O	B-protein
precursor	NN	O	O
,	NN	O	O
(	NN	O	O
b	NN	O	O
)	NN	O	O
conjugation	NN	O	O
of	NN	O	O
ubiquitin	NN	O	B-protein
to	NN	O	O
the	NN	O	O
precursor	NN	O	O
is	NN	O	O
an	NN	O	O
essential	NN	O	O
intermediate	NN	O	O
step	NN	O	O
in	NN	O	O
the	NN	O	O
processing	NN	O	O
,	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
the	NN	O	O
recently	NN	O	O
discovered	NN	O	O
novel	NN	O	O
species	NN	O	O
of	NN	O	O
the	NN	O	O
ubiquitin-carrier	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
E2-F1	NN	O	B-protein
,	NN	O	O
that	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
conjugation	NN	O	O
and	NN	O	O
degradation	NN	O	O
of	NN	O	O
p53	NN	O	B-protein
,	NN	O	O
is	NN	O	O
also	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
limited	NN	O	O
processing	NN	O	O
of	NN	O	O
the	NN	O	O
p105	NN	O	B-protein
precursor	NN	O	I-protein
,	NN	O	O
and	NN	O	O
(	NN	O	O
d	NN	O	O
)	NN	O	O
a	NN	O	O
novel	NN	O	O
,	NN	O	O
approximately	NN	O	O
320-kDa	NN	O	B-protein
species	NN	O	I-protein
of	NN	O	O
ubiquitin-protein	NN	O	B-protein
ligase	NN	O	I-protein
,	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
process	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
investigate	NN	O	O
the	NN	O	O
long-term	NN	O	O
effects	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
flutamide	NN	O	O
on	NN	O	O
clinical	NN	O	O
and	NN	O	O
hormonal	NN	O	O
parameters	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
the	NN	O	O
androgen	NN	O	B-protein
receptor	NN	O	I-protein
status	NN	O	O
,	NN	O	O
in	NN	O	O
hirsute	NN	O	O
women	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Flutamide	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
all	NN	O	O
women	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
noticeable	NN	O	O
exception	NN	O	O
of	NN	O	O
one	NN	O	O
patient	NN	O	O
who	NN	O	O
presented	NN	O	O
increased	NN	O	O
serum	NN	O	B-protein
transaminase	NN	O	I-protein
after	NN	O	O
8	NN	O	O
months	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Androgen	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
might	NN	O	O
be	NN	O	O
potentiated	NN	O	O
by	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
serum	NN	O	O
androgens	NN	O	O
.	NN	O	O

An	NN	O	O
increased	NN	O	O
growth	NN	O	O
rate	NN	O	O
of	NN	O	O
these	NN	O	O
Jurkat-tat	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
as	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
was	NN	O	O
observed	NN	O	O
.	NN	O	O

A	NN	O	O
PEBP2	NN	O	B-protein
alpha/AML-1-related	NN	O	I-protein
factor	NN	O	I-protein
increases	NN	O	O
osteocalcin	NN	O	B-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
through	NN	O	O
its	NN	O	O
binding	NN	O	O
to	NN	O	O
an	NN	O	O
osteoblast-specific	NN	O	B-DNA
cis-acting	NN	O	I-DNA
element	NN	O	I-DNA
.	NN	O	O

To	NN	O	O
identify	NN	O	O
osteoblast-specific	NN	O	B-DNA
cis-acting	NN	O	I-DNA
elements	NN	O	I-DNA
and	NN	O	O
trans-acting	NN	O	B-protein
factors	NN	O	I-protein
,	NN	O	O
we	NN	O	O
initiated	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
promoter	NN	O	B-DNA
of	NN	O	O
a	NN	O	O
mouse	NN	O	B-DNA
osteocalcin	NN	O	I-DNA
gene	NN	O	I-DNA
,	NN	O	O
an	NN	O	O
osteoblast-specific	NN	O	B-DNA
gene	NN	O	I-DNA
.	NN	O	O

The	NN	O	O
sequence	NN	O	O
of	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
elements	NN	O	B-DNA
,	NN	O	O
OSE2	NN	O	O
,	NN	O	O
is	NN	O	O
identical	NN	O	O
to	NN	O	O
the	NN	O	O
DNA-binding	NN	O	B-DNA
site	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
PEBP2	NN	O	B-protein
alpha/AML-1	NN	O	I-protein
transcription	NN	O	I-protein
factors	NN	O	I-protein
,	NN	O	O
the	NN	O	O
mammalian	NN	O	B-protein
homologues	NN	O	I-protein
of	NN	O	O
the	NN	O	O
Drosophila	NN	O	B-protein
Runt	NN	O	I-protein
protein	NN	O	I-protein
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
,	NN	O	O
using	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
,	NN	O	O
recombinant	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
and	NN	O	O
a	NN	O	O
specific	NN	O	O
antiserum	NN	O	O
against	NN	O	O
AML-1	NN	O	B-protein
proteins	NN	O	I-protein
in	NN	O	O
DNA-binding	NN	O	O
assays	NN	O	O
,	NN	O	O
that	NN	O	O
one	NN	O	O
member	NN	O	O
of	NN	O	O
this	NN	O	O
family	NN	O	O
,	NN	O	O
AML-1B	NN	O	B-protein
,	NN	O	O
binds	NN	O	O
specifically	NN	O	O
to	NN	O	O
OSE2	NN	O	O
and	NN	O	O
is	NN	O	O
immunologically	NN	O	O
related	NN	O	O
to	NN	O	O
OSF2	NN	O	B-protein
,	NN	O	O
the	NN	O	O
factor	NN	O	O
present	NN	O	O
in	NN	O	O
osteoblast	NN	O	O
nuclear	NN	O	O
extracts	NN	O	O
that	NN	O	O
binds	NN	O	O
to	NN	O	O
OSE2	NN	O	O
.	NN	O	O

By	NN	O	O
DNA	NN	O	O
cotransfection	NN	O	O
experiments	NN	O	O
,	NN	O	O
we	NN	O	O
also	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
AML-1B	NN	O	B-protein
can	NN	O	O
increase	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
a	NN	O	O
short	NN	O	O
osteocalcin	NN	O	B-DNA
promoter	NN	O	I-DNA
through	NN	O	O
its	NN	O	O
binding	NN	O	O
to	NN	O	O
OSE2	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
evidence	NN	O	O
that	NN	O	O
IBR	NN	O	B-protein
and	NN	O	O
IBF	NN	O	B-protein
are	NN	O	O
most	NN	O	O
likely	NN	O	O
identical	NN	O	O
proteins	NN	O	O
,	NN	O	O
differing	NN	O	O
in	NN	O	O
their	NN	O	O
degree	NN	O	O
of	NN	O	O
glycosylation	NN	O	O
.	NN	O	O

The	NN	O	O
evolutionarily	NN	O	O
conserved	NN	O	O
N-terminal	NN	O	B-protein
half	NN	O	I-protein
of	NN	O	O
IBR/F	NN	O	B-protein
harbors	NN	O	O
the	NN	O	O
DNA-binding/dimerization	NN	O	B-protein
domain	NN	O	I-protein
(	NN	O	O
outer	NN	O	O
limits	NN	O	O
,	NN	O	O
127	NN	O	O
to	NN	O	O
283	NN	O	O
)	NN	O	O
,	NN	O	O
one	NN	O	O
or	NN	O	O
several	NN	O	O
casein	NN	O	B-protein
kinase	NN	O	I-protein
II	NN	O	I-protein
sites	NN	O	I-protein
(	NN	O	O
37	NN	O	O
to	NN	O	O
67	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
bipartite	NN	O	B-protein
nuclear	NN	O	I-protein
localization	NN	O	I-protein
signal	NN	O	I-protein
(	NN	O	O
89	NN	O	O
to	NN	O	O
106	NN	O	O
)	NN	O	O
which	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
necessary	NN	O	O
for	NN	O	O
nuclear	NN	O	O
targeting	NN	O	O
.	NN	O	O

This	NN	O	O
removal	NN	O	O
occurred	NN	O	O
by	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
constitutive	NN	O	B-protein
Sp1	NN	O	I-protein
factor	NN	O	I-protein
,	NN	O	O
whose	NN	O	O
increased	NN	O	O
binding	NN	O	O
activity	NN	O	O
and	NN	O	O
phosphorylation	NN	O	O
were	NN	O	O
mediated	NN	O	O
by	NN	O	O
IFN-gamma	NN	O	B-protein
.	NN	O	O

An	NN	O	O
Epstein-Barr	NN	O	B-cell_line
virus	NN	O	I-cell_line
(	NN	O	I-cell_line
EBV	NN	O	I-cell_line
)	NN	O	I-cell_line
-transformed	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
derived	NN	O	O
from	NN	O	O
her	NN	O	O
lymphocytes	NN	O	B-cell_type
had	NN	O	O
normal	NN	O	O
gamma	NN	O	B-protein
c	NN	O	I-protein
expression	NN	O	O
but	NN	O	O
lacked	NN	O	O
Jak3	NN	O	B-protein
protein	NN	O	I-protein
and	NN	O	O
had	NN	O	O
greatly	NN	O	O
diminished	NN	O	O
Jak3	NN	O	B-RNA
messenger	NN	O	I-RNA
RNA	NN	O	I-RNA
.	NN	O	O

Flow	NN	O	O
cytometry	NN	O	O
showed	NN	O	O
that	NN	O	O
L-selectin	NN	O	B-protein
was	NN	O	O
expressed	NN	O	O
on	NN	O	O
fresh	NN	O	O
ATL	NN	O	B-cell_line
cells	NN	O	I-cell_line
along	NN	O	O
with	NN	O	O
other	NN	O	O
activation	NN	O	B-protein
antigens	NN	O	I-protein
.	NN	O	O

Studies	NN	O	O
using	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
showed	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
L-selectin	NN	O	B-RNA
mRNA	NN	O	I-RNA
in	NN	O	O
the	NN	O	O
infiltrating	NN	O	O
leukemic	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
the	NN	O	O
liver	NN	O	O
of	NN	O	O
two	NN	O	O
ATL	NN	O	O
patients	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
ATL	NN	O	B-cell_line
cells	NN	O	I-cell_line
constitutively	NN	O	O
overexpress	NN	O	O
the	NN	O	O
L-selectin	NN	O	B-DNA
gene	NN	O	I-DNA
that	NN	O	O
can	NN	O	O
be	NN	O	O
transactivated	NN	O	O
by	NN	O	O
HTLV-1	NN	O	O
Tax	NN	O	B-protein
.	NN	O	O

Absorptive	NN	O	O
hypercalciuria	NN	O	O
(	NN	O	O
a	NN	O	O
stone-forming	NN	O	O
condition	NN	O	O
)	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
gut	NN	O	O
hyperabsorption	NN	O	O
of	NN	O	O
calcium	NN	O	O
,	NN	O	O
hypercalciuria	NN	O	O
,	NN	O	O
and	NN	O	O
reduced	NN	O	O
bone	NN	O	O
density	NN	O	O
.	NN	O	O

A	NN	O	O
major	NN	O	O
transcription	NN	O	B-DNA
initiation	NN	O	I-DNA
site	NN	O	I-DNA
was	NN	O	O
located	NN	O	O
in	NN	O	O
three	NN	O	O
human	NN	O	O
tissues	NN	O	O
approximately	NN	O	O
560	NN	O	B-DNA
bp	NN	O	I-DNA
upstream	NN	O	I-DNA
from	NN	O	O
the	NN	O	O
translation	NN	O	B-DNA
initiation	NN	O	I-DNA
codon	NN	O	I-DNA
and	NN	O	O
380	NN	O	B-DNA
bp	NN	O	I-DNA
upstream	NN	O	I-DNA
from	NN	O	O
any	NN	O	O
previously	NN	O	O
identified	NN	O	O
transcription	NN	O	B-DNA
initiation	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Thromboxane	NN	O	O
receptor	NN	O	B-DNA
promoter	NN	O	I-DNA
activity	NN	O	O
,	NN	O	O
as	NN	O	O
assessed	NN	O	O
by	NN	O	O
CAT	NN	O	B-protein
expression	NN	O	O
,	NN	O	O
was	NN	O	O
relatively	NN	O	O
weak	NN	O	O
but	NN	O	O
was	NN	O	O
significantly	NN	O	O
enhanced	NN	O	O
by	NN	O	O
phorbol	NN	O	O
ester	NN	O	O
treatment	NN	O	O
.	NN	O	O

Confirmation	NN	O	O
of	NN	O	O
a	NN	O	O
model	NN	O	O
.	NN	O	O

Proteins	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
group	NN	O	O
contain	NN	O	O
multiple	NN	O	O
HMG	NN	O	B-protein
boxes	NN	O	I-protein
,	NN	O	O
are	NN	O	O
non-sequence-specific	NN	O	O
,	NN	O	O
and	NN	O	O
recognize	NN	O	O
structural	NN	O	O
features	NN	O	O
as	NN	O	O
found	NN	O	O
in	NN	O	O
cruciform	NN	O	B-DNA
DNA	NN	O	I-DNA
and	NN	O	O
cross-over	NN	O	B-DNA
DNA	NN	O	I-DNA
.	NN	O	O

Proteins	NN	O	O
in	NN	O	O
the	NN	O	O
second	NN	O	O
group	NN	O	O
carry	NN	O	O
a	NN	O	O
single	NN	O	B-protein
HMG	NN	O	I-protein
box	NN	O	I-protein
with	NN	O	O
affinity	NN	O	O
for	NN	O	O
the	NN	O	O
minor	NN	O	O
groove	NN	O	O
of	NN	O	O
the	NN	O	O
heptamer	NN	O	B-DNA
motif	NN	O	I-DNA
AACAAAG	NN	O	O
or	NN	O	O
variations	NN	O	O
thereof	NN	O	O
.	NN	O	O

Helices	NN	O	B-protein
I	NN	O	I-protein
and	NN	O	I-protein
II	NN	O	I-protein
are	NN	O	O
positioned	NN	O	O
in	NN	O	O
an	NN	O	O
antiparallel	NN	O	B-protein
mode	NN	O	I-protein
and	NN	O	O
form	NN	O	O
one	NN	O	O
arm	NN	O	O
of	NN	O	O
the	NN	O	O
HMG	NN	O	B-protein
box	NN	O	I-protein
.	NN	O	O

Bik	NN	O	B-protein
,	NN	O	O
a	NN	O	O
novel	NN	O	O
death-inducing	NN	O	B-protein
protein	NN	O	I-protein
shares	NN	O	O
a	NN	O	O
distinct	NN	O	O
sequence	NN	O	O
motif	NN	O	O
with	NN	O	O
Bcl-2	NN	O	B-protein
family	NN	O	I-protein
proteins	NN	O	I-protein
and	NN	O	O
interacts	NN	O	O
with	NN	O	O
viral	NN	O	O
and	NN	O	O
cellular	NN	O	B-protein
survival-promoting	NN	O	I-protein
proteins	NN	O	I-protein
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
expression	NN	O	O
reportedly	NN	O	O
occurs	NN	O	O
in	NN	O	O
multiple	NN	O	O
nonlymphoid	NN	O	O
tissues	NN	O	O
during	NN	O	O
murine	NN	O	O
embryogenesis	NN	O	O
.	NN	O	O

As	NN	O	O
expected	NN	O	O
,	NN	O	O
the	NN	O	O
TCF-1	NN	O	B-protein
protein	NN	O	I-protein
was	NN	O	O
detectable	NN	O	O
only	NN	O	O
in	NN	O	O
cell	NN	O	B-cell_line
lines	NN	O	I-cell_line
of	NN	O	I-cell_line
T	NN	O	I-cell_line
lineage	NN	O	I-cell_line
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
nuclear	NN	O	O
TCF-1	NN	O	B-protein
expression	NN	O	O
can	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
pan-T-lineage	NN	O	O
marker	NN	O	O
in	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
lymphoid	NN	O	O
malignancies	NN	O	O
.	NN	O	O

-DOCSTART-	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
cross-linking	NN	O	O
of	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
RI	NN	O	I-protein
or	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
RII	NN	O	I-protein
by	NN	O	O
adherent	NN	O	B-protein
human	NN	O	I-protein
IgG	NN	O	I-protein
or	NN	O	O
by	NN	O	O
specific	NN	O	O
anti-Fc	NN	O	B-protein
gamma	NN	O	I-protein
R	NN	O	I-protein
mAb	NN	O	I-protein
activates	NN	O	O
HIV-1	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	B-cell_line
monocytic	NN	O	I-cell_line
cell	NN	O	I-cell_line
line	NN	O	I-cell_line
BF24	NN	O	B-cell_line
and	NN	O	O
increased	NN	O	O
HIV	NN	O	B-RNA
RNA	NN	O	I-RNA
expression	NN	O	O
in	NN	O	O
monocytes	NN	O	B-cell_type
from	NN	O	O
HIV	NN	O	O
infected	NN	O	O
patients	NN	O	O
as	NN	O	O
assayed	NN	O	O
by	NN	O	O
reverse	NN	O	O
transcription-PCR	NN	O	O
.	NN	O	O

In	NN	O	O
THP-1	NN	O	B-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
R	NN	O	I-protein
cross-linking	NN	O	O
induced	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
,	NN	O	O
which	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
bind	NN	O	O
to	NN	O	O
the	NN	O	O
regulatory	NN	O	B-DNA
region	NN	O	I-DNA
of	NN	O	O
the	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
(	NN	O	O
LTR	NN	O	B-DNA
)	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
and	NN	O	O
to	NN	O	O
activate	NN	O	O
HIV-1	NN	O	O
transcription	NN	O	O
.	NN	O	O
Anti-TNF-alpha	NN	O	B-protein
antibody	NN	O	I-protein
but	NN	O	O
not	NN	O	O
anti-IL-1	NN	O	B-protein
beta	NN	O	I-protein
antibody	NN	O	I-protein
strongly	NN	O	O
inhibited	NN	O	O
both	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
HIV-1-	NN	O	O
LTR	NN	O	B-DNA
-driven	NN	O	O
transcription	NN	O	O
and	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
by	NN	O	O
Fc	NN	O	B-protein
gamma	NN	O	I-protein
R	NN	O	I-protein
cross-linking	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
CD28	NN	O	B-protein
in	NN	O	O
modulating	NN	O	O
the	NN	O	O
'naive	NN	O	O
'	NN	O	O
neonatal	NN	O	O
T	NN	O	O
cell	NN	O	O
response	NN	O	O
to	NN	O	O
anti-CD2	NN	O	B-protein
-mediated	NN	O	O
activation	NN	O	O
.	NN	O	O

C/EBP	NN	O	B-protein
proteins	NN	O	I-protein
activate	NN	O	O
transcription	NN	O	O
from	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
immunodeficiency	NN	O	I-DNA
virus	NN	O	I-DNA
type	NN	O	I-DNA
1	NN	O	I-DNA
long	NN	O	I-DNA
terminal	NN	O	I-DNA
repeat	NN	O	I-DNA
in	NN	O	O
macrophages/	NN	O	O
monocytes	NN	O	B-cell_type
.	NN	O	O

Northern	NN	O	O
(	NN	O	O
RNA	NN	O	O
)	NN	O	O
blots	NN	O	O
and	NN	O	O
binding	NN	O	O
assays	NN	O	O
showed	NN	O	O
that	NN	O	O
NF-IL6	NN	O	B-protein
is	NN	O	O
the	NN	O	O
only	NN	O	O
known	NN	O	O
C/EBP	NN	O	B-protein
family	NN	O	I-protein
member	NN	O	I-protein
which	NN	O	O
is	NN	O	O
increased	NN	O	O
when	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
are	NN	O	O
activated	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
transcription	NN	O	O
from	NN	O	O
crippled	NN	O	B-DNA
HIV-1	NN	O	I-DNA
LTRs	NN	O	I-DNA
lacking	NN	O	O
C/EBP	NN	O	B-DNA
sites	NN	O	I-DNA
can	NN	O	O
still	NN	O	O
be	NN	O	O
induced	NN	O	O
following	NN	O	O
activation	NN	O	O
of	NN	O	O
U937	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Since	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
viruses	NN	O	O
is	NN	O	O
in	NN	O	O
large	NN	O	O
part	NN	O	O
regulated	NN	O	O
by	NN	O	O
the	NN	O	O
sequence	NN	O	B-DNA
elements	NN	O	I-DNA
in	NN	O	O
their	NN	O	O
long	NN	O	B-DNA
terminal	NN	O	I-DNA
repeats	NN	O	I-DNA
(	NN	O	O
LTRs	NN	O	B-DNA
)	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
directed	NN	O	O
to	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
regulatory	NN	O	B-DNA
elements	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
HIV-2	NN	O	B-DNA
LTR	NN	O	I-DNA
.	NN	O	O

Observations	NN	O	O
such	NN	O	O
as	NN	O	O
these	NN	O	O
encourage	NN	O	O
the	NN	O	O
speculation	NN	O	O
that	NN	O	O
there	NN	O	O
may	NN	O	O
be	NN	O	O
subtle	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
HIV-1	NN	O	O
and	NN	O	O
HIV-2	NN	O	O
expression	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
relevant	NN	O	O
to	NN	O	O
the	NN	O	O
possible	NN	O	O
longer	NN	O	O
latency	NN	O	O
and	NN	O	O
reduced	NN	O	O
pathogenicity	NN	O	O
of	NN	O	O
HIV-2	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
NF-M	NN	O	B-protein
in	NN	O	O
hematopoietic	NN	O	B-cell_line
cell	NN	O	I-cell_line
lineage	NN	O	I-cell_line
commitment	NN	O	O
,	NN	O	O
we	NN	O	O
constructed	NN	O	O
a	NN	O	O
conditional	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
protein	NN	O	O
by	NN	O	O
fusing	NN	O	O
it	NN	O	O
to	NN	O	O
the	NN	O	O
hormone	NN	O	B-protein
binding	NN	O	I-protein
domain	NN	O	I-protein
of	NN	O	O
the	NN	O	O
human	NN	O	B-protein
estrogen	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
these	NN	O	O
parameters	NN	O	O
were	NN	O	O
indistinguishable	NN	O	O
for	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
PRL-	NN	O	B-protein
and	NN	O	I-protein
IL-2-induced	NN	O	I-protein
factors	NN	O	I-protein
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
whether	NN	O	O
such	NN	O	O
adaptive	NN	O	O
changes	NN	O	O
in	NN	O	O
TR	NN	O	B-protein
expression	NN	O	O
occur	NN	O	O
in	NN	O	O
humans	NN	O	O
,	NN	O	O
we	NN	O	O
determined	NN	O	O
the	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
hTR	NN	O	B-protein
beta	NN	O	I-protein
1	NN	O	I-protein
in	NN	O	O
various	NN	O	O
thyroid	NN	O	O
states	NN	O	O
.	NN	O	O

A	NN	O	O
strong	NN	O	O
repressor	NN	O	B-protein
element	NN	O	I-protein
,	NN	O	O
termed	NN	O	O
nuclear	NN	O	B-protein
inhibitory	NN	O	I-protein
protein	NN	O	I-protein
(	NN	O	O
NIP	NN	O	B-protein
)	NN	O	O
,	NN	O	O
was	NN	O	O
previously	NN	O	O
mapped	NN	O	O
to	NN	O	O
a	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
IL-3	NN	O	B-DNA
promoter	NN	O	I-DNA
between	NN	O	O
nucleotides	NN	O	B-DNA
-271	NN	O	I-DNA
and	NN	O	I-DNA
-250	NN	O	I-DNA
.	NN	O	O

Using	NN	O	O
varying	NN	O	O
conditions	NN	O	O
,	NN	O	O
three	NN	O	O
distinct	NN	O	O
complexes	NN	O	O
were	NN	O	O
shown	NN	O	O
to	NN	O	O
interact	NN	O	O
specifically	NN	O	O
with	NN	O	O
the	NN	O	O
NIP	NN	O	B-DNA
region	NN	O	I-DNA
,	NN	O	O
although	NN	O	O
only	NN	O	O
one	NN	O	O
correlates	NN	O	O
with	NN	O	O
repressor	NN	O	O
activity	NN	O	O
.	NN	O	O

PU.1	NN	O	B-protein
is	NN	O	O
a	NN	O	O
hematopoietic	NN	O	B-protein
transcription	NN	O	I-protein
factor	NN	O	I-protein
belonging	NN	O	O
to	NN	O	O
the	NN	O	O
Ets-family	NN	O	B-protein
.	NN	O	O

The	NN	O	O
findings	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	B-cell_line
multiple	NN	O	I-cell_line
myeloma	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
represent	NN	O	O
the	NN	O	O
first	NN	O	O
examples	NN	O	O
of	NN	O	O
B	NN	O	B-cell_type
cells	NN	O	I-cell_type
with	NN	O	O
downregulated	NN	O	O
PU.1	NN	O	B-protein
expression	NN	O	O
and	NN	O	O
apparently	NN	O	O
contradict	NN	O	O
observations	NN	O	O
in	NN	O	O
the	NN	O	O
murine	NN	O	O
system	NN	O	O
in	NN	O	O
which	NN	O	O
PU.1	NN	O	B-protein
is	NN	O	O
expressed	NN	O	O
and	NN	O	O
active	NN	O	O
in	NN	O	O
plasmacytoma	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

At	NN	O	O
present	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
unclear	NN	O	O
whether	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
PU.1	NN	O	B-protein
expression	NN	O	O
and	NN	O	O
activity	NN	O	O
in	NN	O	O
human	NN	O	B-cell_line
multiple	NN	O	I-cell_line
myeloma	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
represents	NN	O	O
a	NN	O	O
malignancy-associated	NN	O	O
defect	NN	O	O
in	NN	O	O
these	NN	O	O
cells	NN	O	O
or	NN	O	O
exemplifies	NN	O	O
a	NN	O	O
normal	NN	O	O
developmental	NN	O	O
regulation	NN	O	O
in	NN	O	O
terminally	NN	O	B-cell_type
differentiated	NN	O	I-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Significantly	NN	O	O
,	NN	O	O
CsA	NN	O	O
completely	NN	O	O
suppressed	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
NFAT	NN	O	B-protein
in	NN	O	O
endothelial	NN	O	B-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
inhibited	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
granulocyte-macrophage	NN	O	B-DNA
colony-stimulating	NN	O	I-DNA
factor	NN	O	I-DNA
(	NN	O	I-DNA
GM-CSF	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
regulatory	NN	O	I-DNA
elements	NN	O	I-DNA
that	NN	O	O
use	NN	O	O
NFAT	NN	O	B-protein
by	NN	O	O
60	NN	O	O
%	NN	O	O
.	NN	O	O

CsA	NN	O	O
also	NN	O	O
suppressed	NN	O	O
E-selectin	NN	O	B-protein
,	NN	O	O
but	NN	O	O
not	NN	O	O
vascular	NN	O	B-protein
cell	NN	O	I-protein
adhesion	NN	O	I-protein
molecule-1	NN	O	I-protein
(	NN	O	O
VCAM-1	NN	O	B-protein
)	NN	O	O
expression	NN	O	O
in	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
,	NN	O	O
even	NN	O	O
though	NN	O	O
the	NN	O	O
E-selectin	NN	O	B-DNA
promoter	NN	O	I-DNA
is	NN	O	O
activated	NN	O	O
by	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
rather	NN	O	O
than	NN	O	O
NFAT	NN	O	B-protein
.	NN	O	O

Hence	NN	O	O
,	NN	O	O
induction	NN	O	O
of	NN	O	O
cell	NN	O	O
surface	NN	O	O
expression	NN	O	O
of	NN	O	O
this	NN	O	O
leukocyte	NN	O	B-protein
adhesion	NN	O	I-protein
molecule	NN	O	I-protein
by	NN	O	O
tumor	NN	O	B-protein
necrosis	NN	O	I-protein
factor	NN	O	I-protein
(	NN	O	I-protein
TNF	NN	O	I-protein
)	NN	O	I-protein
-alpha	NN	O	I-protein
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
40	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
CsA	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
was	NN	O	O
reflected	NN	O	O
by	NN	O	O
a	NN	O	O
29	NN	O	O
%	NN	O	O
decrease	NN	O	O
in	NN	O	O
neutrophil	NN	O	B-cell_type
adhesion	NN	O	O
.	NN	O	O

Several	NN	O	O
transcription	NN	O	B-protein
factors	NN	O	I-protein
participate	NN	O	O
in	NN	O	O
IL-2	NN	O	B-protein
promoter	NN	O	O
activation	NN	O	O
,	NN	O	O
among	NN	O	O
which	NN	O	O
are	NN	O	O
AP-1-like	NN	O	B-protein
factors	NN	O	I-protein
and	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
.	NN	O	O

CD4+	NN	O	B-cell_line
macrophages	NN	O	I-cell_line
in	NN	O	O
tissues	NN	O	O
such	NN	O	O
as	NN	O	O
lung	NN	O	O
,	NN	O	O
skin	NN	O	O
,	NN	O	O
and	NN	O	O
lymph	NN	O	O
nodes	NN	O	O
,	NN	O	O
promyelocytic	NN	O	B-cell_type
cells	NN	O	I-cell_type
in	NN	O	O
bone	NN	O	O
marrow	NN	O	O
,	NN	O	O
and	NN	O	O
peripheral	NN	O	B-cell_type
blood	NN	O	I-cell_type
monocytes	NN	O	I-cell_type
serve	NN	O	O
as	NN	O	O
important	NN	O	O
targets	NN	O	O
and	NN	O	O
reservoirs	NN	O	O
for	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	O
virus	NN	O	O
type	NN	O	O
1	NN	O	O
(	NN	O	O
HIV-1	NN	O	O
)	NN	O	O
replication	NN	O	O
.	NN	O	O

Increased	NN	O	O
intracellular	NN	O	O
stores	NN	O	O
of	NN	O	O
latent	NN	O	B-protein
NF-kappa	NN	O	I-protein
B	NN	O	I-protein
may	NN	O	O
also	NN	O	O
result	NN	O	O
in	NN	O	O
rapid	NN	O	O
inducibility	NN	O	O
of	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
-dependent	NN	O	O
cytokine	NN	O	B-protein
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

Steroid	NN	O	O
mediated	NN	O	O
lysis	NN	O	O
of	NN	O	O
lymphoblasts	NN	O	B-cell_type
requires	NN	O	O
the	NN	O	O
DNA	NN	O	O
binding	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
steroid	NN	O	O
hormone	NN	O	O
receptor	NN	O	O
.	NN	O	O

B	NN	O	O
cell-specific	NN	O	O
transcriptional	NN	O	O
promoter	NN	O	O
activity	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
octamer	NN	O	B-DNA
motif	NN	O	I-DNA
requires	NN	O	O
the	NN	O	O
Oct1	NN	O	B-protein
or	NN	O	O
Oct2	NN	O	B-protein
protein	NN	O	I-protein
and	NN	O	O
additional	NN	O	O
B	NN	O	B-protein
cell-restricted	NN	O	I-protein
cofactors	NN	O	I-protein
.	NN	O	O

One	NN	O	O
such	NN	O	O
cofactor	NN	O	B-protein
,	NN	O	O
BOB.1/OBF.1	NN	O	B-protein
,	NN	O	O
was	NN	O	O
recently	NN	O	O
isolated	NN	O	O
from	NN	O	O
human	NN	O	B-cell_type
B	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
isolation	NN	O	O
and	NN	O	O
detailed	NN	O	O
characterization	NN	O	O
of	NN	O	O
the	NN	O	O
murine	NN	O	B-protein
homolog	NN	O	I-protein
.	NN	O	O

We	NN	O	O
and	NN	O	O
others	NN	O	O
have	NN	O	O
previously	NN	O	O
shown	NN	O	O
that	NN	O	O
the	NN	O	O
nuclear	NN	O	B-protein
protein	NN	O	I-protein
,	NN	O	O
Ets-1	NN	O	B-protein
,	NN	O	O
is	NN	O	O
phosphorylated	NN	O	O
in	NN	O	O
a	NN	O	O
calcium-dependent	NN	O	O
manner	NN	O	O
after	NN	O	O
ligation	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	O
(	NN	O	O
Ig	NN	O	O
)	NN	O	O
M	NN	O	O
on	NN	O	O
B	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
both	NN	O	O
activating	NN	O	O
regions	NN	O	O
of	NN	O	O
Oct-2a	NN	O	B-protein
,	NN	O	O
isolated	NN	O	O
from	NN	O	O
their	NN	O	O
natural	NN	O	O
context	NN	O	O
,	NN	O	O
can	NN	O	O
activate	NN	O	O
transcription	NN	O	O
as	NN	O	O
promoter	NN	O	B-protein
factors	NN	O	I-protein
.	NN	O	O

CD30	NN	O	B-protein
ligation	NN	O	O
induces	NN	O	O
nuclear	NN	O	B-protein
factor-kappa	NN	O	I-protein
B	NN	O	I-protein
activation	NN	O	O
in	NN	O	O
human	NN	O	B-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
in	NN	O	O
human	NN	O	B-cell_line
T	NN	O	I-cell_line
helper	NN	O	I-cell_line
(	NN	O	I-cell_line
Th	NN	O	I-cell_line
)	NN	O	I-cell_line
clones	NN	O	I-cell_line
functionally	NN	O	O
characterized	NN	O	O
as	NN	O	O
being	NN	O	O
of	NN	O	O
the	NN	O	O
type	NN	O	O
0	NN	O	O
,	NN	O	O
type	NN	O	O
1	NN	O	O
and	NN	O	O
type	NN	O	O
2	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
,	NN	O	O
<	NN	O	O
1	NN	O	O
%	NN	O	O
und	NN	O	O
93	NN	O	O
%	NN	O	O
CD30+	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
CD30	NN	O	B-protein
-mediated	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
activation	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
CD30+	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Sexual	NN	O	O
hormones	NN	O	O
,	NN	O	O
through	NN	O	O
their	NN	O	O
receptors	NN	O	B-protein
,	NN	O	O
may	NN	O	O
influence	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
eosinophils	NN	O	B-cell_type
in	NN	O	O
patients	NN	O	O
with	NN	O	O
VKC	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
long	NN	O	O
been	NN	O	O
a	NN	O	O
puzzle	NN	O	O
that	NN	O	O
MHC	NN	O	B-protein
class	NN	O	I-protein
II	NN	O	I-protein
molecules	NN	O	I-protein
are	NN	O	O
expressed	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
after	NN	O	O
activation	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
mouse	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
;	NN	O	O
this	NN	O	O
expression	NN	O	O
is	NN	O	O
believed	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
cell	NN	O	O
mediated	NN	O	O
immune	NN	O	O
response	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
expressing	NN	O	O
MHC	NN	O	O
class	NN	O	O
II	NN	O	O
have	NN	O	O
CIITA	NN	O	B-protein
transcripts	NN	O	O
while	NN	O	O
MHC	NN	O	O
class	NN	O	O
II-negative	NN	O	O
human	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
and	NN	O	O
mouse	NN	O	B-cell_type
T	NN	O	I-cell_type
cells	NN	O	I-cell_type
do	NN	O	O
not	NN	O	O
.	NN	O	O

This	NN	O	O
RFLP	NN	O	B-DNA
pair	NN	O	I-DNA
occurs	NN	O	O
in	NN	O	O
76	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
Ro	NN	O	B-protein
(	NN	O	I-protein
SSA	NN	O	I-protein
)	NN	O	I-protein
precipitins	NN	O	O
,	NN	O	O
84	NN	O	O
%	NN	O	O
of	NN	O	O
anti-	NN	O	O
Ro	NN	O	B-protein
(	NN	O	I-protein
SSA	NN	O	I-protein
)	NN	O	I-protein
-positive	NN	O	O
patients	NN	O	O
lacking	NN	O	O
La	NN	O	B-protein
(	NN	O	I-protein
SSB	NN	O	I-protein
)	NN	O	I-protein
precipitins	NN	O	B-protein
,	NN	O	O
but	NN	O	O
only	NN	O	O
41	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
lacking	NN	O	O
both	NN	O	O
precipitins	NN	O	B-protein
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.0004	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
competition	NN	O	O
between	NN	O	O
two	NN	O	O
general	NN	O	O
transcriptional	NN	O	B-protein
activators	NN	O	I-protein
,	NN	O	O
RelA	NN	O	B-protein
and	NN	O	O
NF-ATp	NN	O	B-protein
,	NN	O	O
mediates	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
protein	NN	O	B-protein
kinase	NN	O	I-protein
C	NN	O	I-protein
stimulation	NN	O	O
on	NN	O	O
IL4	NN	O	B-protein
expression	NN	O	O
and	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
differential	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
TH	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

Exposure	NN	O	O
to	NN	O	O
SFs	NN	O	B-cell_type
during	NN	O	O
priming	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
81	NN	O	O
%	NN	O	O
inhibition	NN	O	O
of	NN	O	O
interferon	NN	O	B-protein
(	NN	O	I-protein
IFN	NN	O	I-protein
)	NN	O	I-protein
-gamma	NN	O	I-protein
,	NN	O	O
but	NN	O	O
not	NN	O	O
interleukin	NN	O	B-protein
(	NN	O	I-protein
IL	NN	O	I-protein
)	NN	O	I-protein
4	NN	O	I-protein
,	NN	O	O
production	NN	O	O
by	NN	O	O
effector	NN	O	B-cell_type
cells	NN	O	I-cell_type
generated	NN	O	O
in	NN	O	O
priming	NN	O	O
cultures	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
observations	NN	O	O
suggest	NN	O	O
that	NN	O	O
HIV	NN	O	O
gene	NN	O	O
expression	NN	O	O
may	NN	O	O
be	NN	O	O
activated	NN	O	O
in	NN	O	O
infected	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
through	NN	O	O
interaction	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
with	NN	O	O
complement-opsonized	NN	O	B-protein
particles	NN	O	I-protein
and	NN	O	O
that	NN	O	O
enhanced	NN	O	O
viral	NN	O	O
replication	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
C3	NN	O	B-protein
receptor	NN	O	I-protein
-mediated	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
the	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
complex	NN	O	I-protein
.	NN	O	O

Attenuation	NN	O	O
of	NN	O	O
gamma	NN	O	B-protein
interferon	NN	O	I-protein
-induced	NN	O	O
tyrosine	NN	O	O
phosphorylation	NN	O	O
in	NN	O	O
mononuclear	NN	O	B-cell_type
phagocytes	NN	O	I-cell_type
infected	NN	O	O
with	NN	O	O
Leishmania	NN	O	O
donovani	NN	O	O
:	NN	O	O
selective	NN	O	O
inhibition	NN	O	O
of	NN	O	O
signaling	NN	O	O
through	NN	O	O
Janus	NN	O	B-protein
kinases	NN	O	I-protein
and	NN	O	O
Stat1	NN	O	B-protein
.	NN	O	O

Mutually	NN	O	O
exclusive	NN	O	O
interaction	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
matrix	NN	O	B-protein
attachment	NN	O	I-protein
region	NN	O	I-protein
binding	NN	O	I-protein
protein	NN	O	I-protein
and	NN	O	O
the	NN	O	O
NF-muNR	NN	O	B-protein
enhancer	NN	O	I-protein
repressor	NN	O	I-protein
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
demonstration	NN	O	O
of	NN	O	O
a	NN	O	O
specific	NN	O	O
interaction	NN	O	O
with	NN	O	O
PU.1	NN	O	B-protein
on	NN	O	O
a	NN	O	O
myeloid	NN	O	B-DNA
PU.1	NN	O	I-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

Tyrosine	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
this	NN	O	O
protein	NN	O	O
could	NN	O	O
also	NN	O	O
be	NN	O	O
induced	NN	O	O
in	NN	O	O
Balb/c3T3	NN	O	B-cell_line
cells	NN	O	I-cell_line
using	NN	O	O
a	NN	O	O
supernatant	NN	O	O
from	NN	O	O
the	NN	O	O
B	NN	O	B-cell_line
line	NN	O	I-cell_line
,	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
induction	NN	O	O
of	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
.	NN	O	O

HU	NN	O	O
induced	NN	O	O
a	NN	O	O
dose-dependent	NN	O	O
stimulation	NN	O	O
of	NN	O	O
c-jun	NN	O	B-DNA
synthesis	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
concentrations	NN	O	O
of	NN	O	O
HU	NN	O	O
below	NN	O	O
250	NN	O	O
microM	NN	O	O
slightly	NN	O	O
increased	NN	O	O
the	NN	O	O
5X	NN	O	O
AP-1	NN	O	B-protein
/CAT	NN	O	B-protein
activity	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
PWM	NN	O	B-protein
-induced	NN	O	O
B-cell	NN	O	O
mitogenesis	NN	O	O
and	NN	O	O
a	NN	O	O
more	NN	O	O
pronounced	NN	O	O
effect	NN	O	O
of	NN	O	O
DEX	NN	O	O
administered	NN	O	O
in	NN	O	O
vitro	NN	O	O
on	NN	O	O
spontaneous	NN	O	O
lymphocyte	NN	O	O
proliferation	NN	O	O
after	NN	O	O
MET	NN	O	O
treatment	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
DEX	NN	O	O
plus	NN	O	O
MET	NN	O	O
pretreated	NN	O	O
condition	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
lymphocyte	NN	O	O
proliferation	NN	O	O
by	NN	O	O
glucocorticoids	NN	O	O
in	NN	O	O
vitro	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
glucocorticoid	NN	O	B-protein
receptor	NN	O	I-protein
function	NN	O	O
.	NN	O	O

Application	NN	O	O
of	NN	O	O
a	NN	O	O
``	NN	O	O
formamide	NN	O	O
free	NN	O	O
''	NN	O	O
and	NN	O	O
thus	NN	O	O
``	NN	O	O
material	NN	O	O
preserving	NN	O	O
''	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
technique	NN	O	O
using	NN	O	O
the	NN	O	O
cDNA	NN	O	B-DNA
of	NN	O	O
the	NN	O	O
myf3	NN	O	B-DNA
gene	NN	O	I-DNA
revealed	NN	O	O
the	NN	O	O
following	NN	O	O
results	NN	O	O
:	NN	O	O
Human	NN	O	B-cell_type
rhabdomyosarcoma	NN	O	I-cell_type
cells	NN	O	I-cell_type
,	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
high	NN	O	O
expression	NN	O	O
of	NN	O	O
myf3	NN	O	B-DNA
show	NN	O	O
intensive	NN	O	O
hybridization	NN	O	O
signals	NN	O	O
in	NN	O	O
their	NN	O	O
interphase	NN	O	O
.	NN	O	O

-DOCSTART-	O

The	NN	O	O
ability	NN	O	O
of	NN	O	O
IFN-activated	NN	O	B-cell_line
NK	NN	O	I-cell_line
cells	NN	O	I-cell_line
to	NN	O	O
selectively	NN	O	O
kill	NN	O	O
virally	NN	O	O
transformed	NN	O	O
cells	NN	O	O
depends	NN	O	O
on	NN	O	O
IFN	NN	O	B-protein
's	NN	O	O
ability	NN	O	O
to	NN	O	O
induce	NN	O	O
resistance	NN	O	O
to	NN	O	O
NK	NN	O	O
cell	NN	O	O
lysis	NN	O	O
in	NN	O	O
normal	NN	O	O
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
non-viral	NN	O	B-cell_line
oncogene-expressing	NN	O	I-cell_line
)	NN	O	O
but	NN	O	O
not	NN	O	O
virally	NN	O	B-cell_line
transformed	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
IFN	NN	O	B-protein
-induced	NN	O	O
NK	NN	O	O
cell	NN	O	O
killing	NN	O	O
of	NN	O	O
E1A-expressing	NN	O	B-cell_line
cells	NN	O	I-cell_line
was	NN	O	O
proportional	NN	O	O
to	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
E1A	NN	O	B-protein
expression	NN	O	O
and	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
E1A	NN	O	B-protein
to	NN	O	O
block	NN	O	O
IFN	NN	O	B-protein
-stimulated	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
target	NN	O	B-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

Contrary	NN	O	O
to	NN	O	O
the	NN	O	O
interaction	NN	O	O
with	NN	O	O
PKC	NN	O	B-protein
,	NN	O	O
Ca	NN	O	O
(	NN	O	O
2+	NN	O	O
)	NN	O	O
-dependent	NN	O	O
pathways	NN	O	O
synergize	NN	O	O
with	NN	O	O
TNF-alpha	NN	O	B-protein
not	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
IkB	NN	O	B-protein
alpha	NN	O	I-protein
phosphorylation	NN	O	O
,	NN	O	O
but	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
its	NN	O	O
degradation	NN	O	O
.	NN	O	O

They	NN	O	O
inhibit	NN	O	O
synthesis	NN	O	O
of	NN	O	O
almost	NN	O	O
all	NN	O	O
known	NN	O	O
cytokines	NN	O	B-protein
and	NN	O	O
of	NN	O	O
several	NN	O	O
cell	NN	O	B-protein
surface	NN	O	I-protein
molecules	NN	O	I-protein
required	NN	O	O
for	NN	O	O
immune	NN	O	O
function	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
mechanism	NN	O	O
underlying	NN	O	O
this	NN	O	O
activity	NN	O	O
has	NN	O	O
been	NN	O	O
unclear.	NN	O	O
Here	NN	O	O
it	NN	O	O
is	NN	O	O
shown	NN	O	O
that	NN	O	O
glucocorticoids	NN	O	O
are	NN	O	O
potent	NN	O	O
inhibitors	NN	O	O
of	NN	O	O
nuclear	NN	O	B-protein
factor	NN	O	I-protein
kappa	NN	O	I-protein
B	NN	O	I-protein
(	NN	O	O
NF-kappa	NN	O	B-protein
B	NN	O	I-protein
)	NN	O	O
activation	NN	O	O
in	NN	O	O
mice	NN	O	O
and	NN	O	O
cultured	NN	O	B-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

T-lymphocyte	NN	O	O
proliferation	NN	O	O
is	NN	O	O
suppressed	NN	O	O
by	NN	O	O
1	NN	O	O
,	NN	O	O
25-dihydroxyvitamin	NN	O	O
D3	NN	O	O
[	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D3	NN	O	O
]	NN	O	O
,	NN	O	O
the	NN	O	O
active	NN	O	O
metabolite	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
,	NN	O	O
and	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
interleukin	NN	O	O
2	NN	O	O
(	NN	O	O
IL-2	NN	O	O
)	NN	O	O
,	NN	O	O
gamma	NN	O	O
interferon	NN	O	O
,	NN	O	O
and	NN	O	O
granulocyte-macrophage	NN	O	O
colony-stimulating	NN	O	O
factor	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
.	NN	O	O

By	NN	O	O
combining	NN	O	O
partially	NN	O	B-protein
purified	NN	O	I-protein
proteins	NN	O	I-protein
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
the	NN	O	O
bound	NN	O	O
NFATp/AP-1-DNA	NN	O	B-protein
complex	NN	O	I-protein
upon	NN	O	O
inclusion	NN	O	O
of	NN	O	O
VDR	NN	O	B-protein
or	NN	O	O
VDR-retinoid	NN	O	B-protein
X	NN	O	I-protein
receptor	NN	O	I-protein
.	NN	O	O

This	NN	O	O
direct	NN	O	O
inhibition	NN	O	O
by	NN	O	O
a	NN	O	O
nuclear	NN	O	O
hormone	NN	O	O
receptor	NN	O	O
of	NN	O	O
transcriptional	NN	O	B-protein
activators	NN	O	I-protein
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-DNA
gene	NN	O	I-DNA
may	NN	O	O
provide	NN	O	O
a	NN	O	O
mechanistic	NN	O	O
explanation	NN	O	O
of	NN	O	O
how	NN	O	O
vitamin	NN	O	O
derivatives	NN	O	O
can	NN	O	O
act	NN	O	O
as	NN	O	O
potent	NN	O	O
immunosuppressive	NN	O	O
agents	NN	O	O
.	NN	O	O

-DOCSTART-	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
,	NN	O	O
cysteamine	NN	O	O
,	NN	O	O
an	NN	O	O
aminothiol	NN	O	O
compound	NN	O	O
with	NN	O	O
antioxidant	NN	O	O
activity	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
further	NN	O	O
investigate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
oxidative	NN	O	O
signalling	NN	O	O
during	NN	O	O
lymphocyte	NN	O	O
activation	NN	O	O
.	NN	O	O

Cysteamine	NN	O	O
treatment	NN	O	O
inhibited	NN	O	O
both	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
IL-2	NN	O	B-RNA
mRNA	NN	O	I-RNA
and	NN	O	O
secretion	NN	O	O
of	NN	O	O
IL-2	NN	O	B-protein
into	NN	O	O
the	NN	O	O
culture	NN	O	O
medium	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
tried	NN	O	O
to	NN	O	O
find	NN	O	O
out	NN	O	O
whether	NN	O	O
these	NN	O	O
receptors	NN	O	O
could	NN	O	O
show	NN	O	O
any	NN	O	O
difference	NN	O	O
in	NN	O	O
sex	NN	O	O
or	NN	O	O
age	NN	O	O
distribution	NN	O	O
.	NN	O	O

No	NN	O	O
difference	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
pre	NN	O	O
and	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
Id2	NN	O	O
and	NN	O	O
Id3	NN	O	O
mRNA	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
lymphocytes	NN	O	I-cell_type
.	NN	O	O

The	NN	O	O
Id2	NN	O	B-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
abundantly	NN	O	O
expressed	NN	O	O
in	NN	O	O
5/12	NN	O	B-cell_line
T-cell	NN	O	I-cell_line
and	NN	O	O
3/4	NN	O	B-cell_line
B-cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
,	NN	O	O
and	NN	O	O
Id3	NN	O	B-RNA
mRNA	NN	O	I-RNA
was	NN	O	O
detected	NN	O	O
in	NN	O	O
4/12	NN	O	B-cell_line
T-cell	NN	O	I-cell_line
and	NN	O	O
3/4	NN	O	B-cell_line
B-cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

Salicylates	NN	O	O
inhibit	NN	O	O
lipopolysaccharide-induced	NN	O	O
transcriptional	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
tissue	NN	O	O
factor	NN	O	O
gene	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytic	NN	O	I-cell_type
cells	NN	O	I-cell_type
.	NN	O	O

TF	NN	O	O
expression	NN	O	O
by	NN	O	O
circulating	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
is	NN	O	O
associated	NN	O	O
with	NN	O	O
thrombotic	NN	O	O
and	NN	O	O
inflammatory	NN	O	O
complications	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
diseases	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
a	NN	O	O
family	NN	O	O
of	NN	O	O
anti-inflammatory	NN	O	O
agents	NN	O	O
,	NN	O	O
known	NN	O	O
as	NN	O	O
the	NN	O	O
salicylates	NN	O	O
,	NN	O	O
inhibited	NN	O	O
LPS	NN	O	O
induction	NN	O	O
of	NN	O	O
TF	NN	O	O
activity	NN	O	O
and	NN	O	O
TF	NN	O	B-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
in	NN	O	O
human	NN	O	B-cell_type
monocytes	NN	O	I-cell_type
and	NN	O	O
monocytic	NN	O	B-cell_line
THP-1	NN	O	I-cell_line
cells	NN	O	I-cell_line
at	NN	O	O
clinically	NN	O	O
relevant	NN	O	O
doses	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
salicylates	NN	O	O
inhibited	NN	O	O
LPS	NN	O	O
induction	NN	O	O
of	NN	O	O
TF	NN	O	B-DNA
gene	NN	O	I-DNA
transcription	NN	O	O
in	NN	O	O
monocytic	NN	O	B-cell_type
cells	NN	O	I-cell_type
by	NN	O	O
preventing	NN	O	O
nuclear	NN	O	O
translocation	NN	O	O
of	NN	O	O
c-Rel/p65	NN	O	B-protein
heterodimers	NN	O	I-protein
.	NN	O	O

These	NN	O	O
STAT	NN	O	B-protein
proteins	NN	O	I-protein
were	NN	O	O
detected	NN	O	O
by	NN	O	O
using	NN	O	O
the	NN	O	O
IFN-gamma-activated	NN	O	B-DNA
sequence	NN	O	I-DNA
(	NN	O	O
GAS	NN	O	B-DNA
)	NN	O	O
and	NN	O	O
related	NN	O	O
oligonucleotides	NN	O	O
as	NN	O	O
probes	NN	O	O
in	NN	O	O
electrophoretic	NN	O	O
mobility	NN	O	O
shift	NN	O	O
assay	NN	O	O
.	NN	O	O

As	NN	O	O
neutralizing	NN	O	B-protein
anti-IL-6	NN	O	I-protein
Abs	NN	O	I-protein
effectively	NN	O	O
down-regulated	NN	O	O
the	NN	O	O
early	NN	O	O
induction	NN	O	O
of	NN	O	O
STAT	NN	O	B-protein
proteins	NN	O	I-protein
and	NN	O	O
as	NN	O	O
exogenously	NN	O	O
added	NN	O	O
IL-6	NN	O	B-protein
rapidly	NN	O	O
activated	NN	O	O
DNA	NN	O	O
binding	NN	O	O
similar	NN	O	O
to	NN	O	O
TCR	NN	O	B-protein
-mediated	NN	O	O
bindings	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
concluded	NN	O	O
that	NN	O	O
IL-6	NN	O	B-protein
is	NN	O	O
the	NN	O	O
factor	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
STAT	NN	O	B-protein
proteins	NN	O	I-protein
in	NN	O	O
a	NN	O	O
primary	NN	O	O
T	NN	O	O
cell	NN	O	O
response	NN	O	O
.	NN	O	O

Antigen	NN	O	O
recognition	NN	O	O
stimulates	NN	O	O
limited	NN	O	O
proliferation	NN	O	O
,	NN	O	O
whereas	NN	O	O
infection	NN	O	O
with	NN	O	O
Epstein-Barr	NN	O	O
virus	NN	O	O
(	NN	O	O
EBV	NN	O	O
)	NN	O	O
results	NN	O	O
in	NN	O	O
continual	NN	O	O
proliferation	NN	O	O
and	NN	O	O
the	NN	O	O
outgrowth	NN	O	O
of	NN	O	O
immortal	NN	O	B-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
.	NN	O	O

Because	NN	O	O
these	NN	O	O
genes	NN	O	O
play	NN	O	O
a	NN	O	O
positive	NN	O	O
role	NN	O	O
in	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
,	NN	O	O
we	NN	O	O
suggest	NN	O	O
that	NN	O	O
this	NN	O	O
regulatory	NN	O	O
switch	NN	O	O
contributes	NN	O	O
to	NN	O	O
controlling	NN	O	O
entry	NN	O	O
into	NN	O	O
the	NN	O	O
cell	NN	O	O
cycle	NN	O	O
.	NN	O	O

Transient	NN	O	O
stimulation	NN	O	O
of	NN	O	O
quiescent	NN	O	B-cell_type
B	NN	O	I-cell_type
lymphocytes	NN	O	I-cell_type
with	NN	O	O
either	NN	O	O
a	NN	O	O
cocktail	NN	O	O
of	NN	O	O
anti-CD40	NN	O	B-protein
,	NN	O	O
anti-IgM	NN	O	B-protein
,	NN	O	O
and	NN	O	O
IL4	NN	O	B-protein
,	NN	O	O
or	NN	O	O
EBV	NN	O	O
results	NN	O	O
in	NN	O	O
the	NN	O	O
rapid	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
four	NN	O	O
genes	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
,	NN	O	O
after	NN	O	O
infection	NN	O	O
,	NN	O	O
EBV	NN	O	O
exploits	NN	O	O
the	NN	O	O
normal	NN	O	O
program	NN	O	O
of	NN	O	O
B-lymphocyte	NN	O	B-cell_type
cell	NN	O	O
cycle	NN	O	O
activation	NN	O	O
.	NN	O	O

-DOCSTART-	O

We	NN	O	O
show	NN	O	O
that	NN	O	O
transcription	NN	O	O
of	NN	O	O
the	NN	O	O
BLR2	NN	O	B-DNA
gene	NN	O	I-DNA
could	NN	O	O
be	NN	O	O
specifically	NN	O	O
induced	NN	O	O
in	NN	O	O
Epstein-Barr	NN	O	B-cell_line
virus	NN	O	I-cell_line
negative	NN	O	I-cell_line
BL	NN	O	I-cell_line
41	NN	O	I-cell_line
cells	NN	O	I-cell_line
via	NN	O	O
estrogen-mediated	NN	O	O
activation	NN	O	O
of	NN	O	O
Epstein-Barr	NN	O	B-protein
virus	NN	O	I-protein
nuclear	NN	O	I-protein
antigen	NN	O	I-protein
2	NN	O	I-protein
,	NN	O	O
a	NN	O	O
key	NN	O	O
regulator	NN	O	O
of	NN	O	O
viral	NN	O	B-DNA
and	NN	O	I-DNA
cellular	NN	O	I-DNA
genes	NN	O	I-DNA
in	NN	O	O
immortalized	NN	O	B-cell_line
B	NN	O	I-cell_line
cells	NN	O	I-cell_line
.	NN	O	O

A	NN	O	O
central	NN	O	O
role	NN	O	O
for	NN	O	O
a	NN	O	O
single	NN	O	B-DNA
c-Myb	NN	O	I-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
in	NN	O	O
a	NN	O	O
thymic	NN	O	B-DNA
locus	NN	O	I-DNA
control	NN	O	I-DNA
region	NN	O	I-DNA
.	NN	O	O

We	NN	O	O
now	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
core	NN	O	O
contains	NN	O	O
a	NN	O	O
single	NN	O	O
critical	NN	O	O
c-Myb	NN	O	B-DNA
binding	NN	O	I-DNA
site	NN	O	I-DNA
.	NN	O	O

In	NN	O	O
both	NN	O	O
transiently	NN	O	B-cell_line
cotransfected	NN	O	I-cell_line
human	NN	O	I-cell_line
cells	NN	O	I-cell_line
and	NN	O	O
stable	NN	O	O
chromatin-integrated	NN	O	B-cell_line
yeast	NN	O	I-cell_line
cells	NN	O	I-cell_line
,	NN	O	O
c-Myb	NN	O	B-protein
strongly	NN	O	O
transactivated	NN	O	B-DNA
reporter	NN	O	I-DNA
constructs	NN	O	I-DNA
that	NN	O	O
contained	NN	O	O
polymerized	NN	O	B-DNA
core	NN	O	I-DNA
sequences	NN	O	I-DNA
.	NN	O	O

Within	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
a	NN	O	O
complex	NN	O	B-DNA
enhancer	NN	O	I-DNA
and	NN	O	O
LCR	NN	O	B-DNA
,	NN	O	O
c-Myb	NN	O	B-protein
can	NN	O	O
act	NN	O	O
as	NN	O	O
an	NN	O	O
organizer	NN	O	O
of	NN	O	O
thymocyte-specific	NN	O	B-DNA
gene	NN	O	I-DNA
expression	NN	O	O
via	NN	O	O
a	NN	O	O
single	NN	O	O
binding	NN	O	O
site	NN	O	O
.	NN	O	O

A	NN	O	O
regulatory	NN	O	B-DNA
element	NN	O	I-DNA
in	NN	O	O
the	NN	O	O
human	NN	O	B-DNA
interleukin	NN	O	I-DNA
2	NN	O	I-DNA
gene	NN	O	I-DNA
promoter	NN	O	I-DNA
is	NN	O	O
a	NN	O	O
binding	NN	O	B-DNA
site	NN	O	I-DNA
for	NN	O	O
the	NN	O	O
zinc	NN	O	B-protein
finger	NN	O	I-protein
proteins	NN	O	I-protein
Sp1	NN	O	B-protein
and	NN	O	O
EGR-1	NN	O	B-protein
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
interleukin	NN	O	B-DNA
2	NN	O	I-DNA
(	NN	O	I-DNA
IL-2	NN	O	I-DNA
)	NN	O	I-DNA
gene	NN	O	I-DNA
after	NN	O	O
antigen	NN	O	O
recognition	NN	O	O
is	NN	O	O
a	NN	O	O
critical	NN	O	O
event	NN	O	O
for	NN	O	O
T	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
effector	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
stimulatory	NN	O	O
effects	NN	O	O
of	NN	O	O
gp160	NN	O	B-protein
are	NN	O	O
mediated	NN	O	O
through	NN	O	O
the	NN	O	O
CD4	NN	O	B-protein
molecule	NN	O	I-protein
,	NN	O	O
since	NN	O	O
treatment	NN	O	O
of	NN	O	O
gp160	NN	O	B-protein
with	NN	O	O
soluble	NN	O	O
CD4-IgG	NN	O	B-protein
abrogates	NN	O	O
its	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
CD4	NN	O	B-cell_line
negative	NN	O	I-cell_line
T	NN	O	I-cell_line
cell	NN	O	I-cell_line
lines	NN	O	I-cell_line
fail	NN	O	O
to	NN	O	O
be	NN	O	O
stimulated	NN	O	O
with	NN	O	O
gp160	NN	O	B-protein
.	NN	O	O

